sotalol and Atrioventricular Nodal Re-Entrant Tachycardia studies

Sotalol: An adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmias.
sotalol : A sulfonamide that is N-phenylmethanesulfonamide in which the phenyl group is substituted at position 4 by a 1-hydroxy-2-(isopropylamino)ethyl group. It has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties. It is used (usually as the hydrochloride salt) for the management of ventricular and supraventricular arrhythmias.

Research Excerpts

Excerpt	Relevance	Reference
"To determine the spontaneous variability of ventricular arrhythmias (VA) and evaluate anti-arrhythmic efficacy of mexiletine, sotalol, and a mexiletine-sotalol combination in German shepherd dogs (GSD) with inherited arrhythmias."	9.14	Combination therapy with mexiletine and sotalol suppresses inherited ventricular arrhythmias in German shepherd dogs better than mexiletine or sotalol monotherapy: a randomized cross-over study. ( Gelzer, AR; Hemsley, SA; Kraus, MS; Moïse, NS; Rishniw, M, 2010)
"To evaluate the effects of sotalol in patients with nonsustained ventricular tachyarrhythmia (NSVT)."	9.08	[Brazilian multicenter study of sotalol effectiveness in ventricular arrhythmias]. ( Atie, J; Darwich, R; de Paola, AA; Gizzi, JC; Lorga, AM; Maia, IG; Perez, AK; Rassi, A; Sobral, D, 1996)
"To establish the value of adjuvant dl-sotalol to digoxin for control of the ventricular response in chronic atrial fibrillation, 60 patients were evaluated in a multicenter, randomized, double-blind, parallel, placebo-controlled study."	9.07	Comparative effects of the combination of digoxin and dl-sotalol therapy versus digoxin monotherapy for control of ventricular response in chronic atrial fibrillation. dl-Sotalol Atrial Fibrillation Study Group. ( Bellinger, R; Brodsky, M; Powers, L; Saini, R; Weiss, R; Zoble, R, 1994)
"Our objective was to evaluate the efficacy and safety of intravenous (IV) sotalol in the treatment of incessant tachyarrhythmias in children with normal cardiac function."	7.85	Efficacy of Intravenous Sotalol for Treatment of Incessant Tachyarrhythmias in Children. ( Ge, H; Jiang, H; Li, X; Liu, H; Zhang, Y, 2017)
"The effects of d,l-sotalol at therapeutic concentrations (	7.75	d,l-Sotalol at therapeutic concentrations facilitates the occurrence of long-lasting non-stationary reentry during ventricular fibrillation in isolated rabbit hearts. ( Horng, TL; Hsieh, YC; Lin, SF; Lin, TC; Ting, CT; Wu, TJ, 2009)
"We sought to determine the yield of in-hospital monitoring for detection of significant arrhythmia complications in patients starting sotalol therapy for atrial arrhythmias and to identify factors that might predict safe outpatient initiation."	7.70	Is hospital admission for initiation of antiarrhythmic therapy with sotalol for atrial arrhythmias required? Yield of in-hospital monitoring and prediction of risk for significant arrhythmia complications. ( Chung, MK; Jaeger, FJ; Kidwell, GA; Miller, DP; Morant, VA; Niebauer, MJ; Pinski, SL; Schweikert, RA; Tchou, PJ; Trohman, RG; Wilkoff, BL, 1998)
"We compared the ability of a new amiodarone-like agent, SR 33589, with that of amiodarone, D,L-sotalol, and lignocaine to reduce the incidence of ventricular fibrillation (VF) and associated arrhythmias caused by acute coronary artery occlusion in anesthetized pigs."	7.69	Effects of a new amiodarone-like agent, SR 33589, in comparison to amiodarone, D,L-sotalol, and lignocaine, on ischemia-induced ventricular arrhythmias in anesthetized pigs. ( Chatelain, P; Finance, O; Manning, A, 1995)
"The efficacy and safety of sotalol therapy for ventricular arrhythmias was evaluated in 133 patients with drug-refractory ventricular arrhythmias."	7.69	Long-term results of electrophysiologically guided sotalol therapy for life-threatening ventricular arrhythmias. ( Epstein, LM; Fitzpatrick, AP; Grogin, HR; Lee, RJ; Lesh, MD; Namekawa-Wong, M; Scheinman, MM; Siu, A; Wong, M, 1996)
"We explored the central hemodynamic responses to oral sotalol during dose titration in patients with ventricular arrhythmias who underwent programmed ventricular stimulation."	7.68	Effect of oral sotalol on systemic hemodynamics and programmed electrical stimulation in patients with ventricular arrhythmias and structural heart disease. ( Deitchman, D; Gomes, JA; Kukin, M; Pe, E; Stewart, D; Winters, SL, 1993)
"Sotalol is a unique antiarrhythmic drug that combines beta-blocking effects with actions to prolong action potential duration."	6.38	Practical considerations in the use of sotalol for ventricular tachycardia and ventricular fibrillation. ( Campbell, RW; Furniss, SS, 1993)
"This study suggests that flecainide and beta-blockers association is complementary to implantable cardioverter-defibrillator and catheter ablation and is safe for treating persistent symptomatic VA in patients with ARVC."	5.72	Safety and efficacy of flecainide associated with beta-blockers in arrhythmogenic right ventricular cardiomyopathy. ( Badenco, N; Duthoit, G; Frank, R; Gandjbakhch, E; Hidden-Lucet, F; Himbert, C; Laredo, M; Maupain, C; Rolland, T; Waintraub, X, 2022)
"Ivabradine treatment resulted in occurrence of EAD and polymorphic VT in 9 of 12 sotalol-treated hearts (212 episodes), and 8 of 12 veratridine-treated hearts (155 episodes)."	5.51	Ivabradine Aggravates the Proarrhythmic Risk in Experimental Models of Long QT Syndrome. ( Dechering, DG; Eckardt, L; Ellermann, C; Frommeyer, G; Kochhäuser, S; Lange, PS; Leitz, P; Weller, J, 2019)
"Sustained ventricular tachycardia was induced by programmed stimulation in dogs 4 days after left anterior coronary artery occlusion and reentrant circuits in the epicardial border zone (EBZ) mapped."	5.32	Beta receptor blockade potentiates the antiarrhythmic actions of d-sotalol on reentrant ventricular tachycardia in a canine model of myocardial infarction. ( Cabo, C; Coromilas, J; Kassotis, J; Sauberman, RB; Wit, AL, 2003)
" The history of this approach has been disappointing, marked by catastrophic failures such as those of sodium channel blockers or sotalol to treat ventricular arrhythmias in the setting of structural cardiomyopathies, which led to increased mortality, and by modest clinical efficacy in paroxysmal atrial fibrillation."	5.22	The Future of Antiarrhythmic Drug Therapy: Will Drugs Be Entirely Replaced by Procedures? ( Valderrábano, M, 2022)
"To determine the spontaneous variability of ventricular arrhythmias (VA) and evaluate anti-arrhythmic efficacy of mexiletine, sotalol, and a mexiletine-sotalol combination in German shepherd dogs (GSD) with inherited arrhythmias."	5.14	Combination therapy with mexiletine and sotalol suppresses inherited ventricular arrhythmias in German shepherd dogs better than mexiletine or sotalol monotherapy: a randomized cross-over study. ( Gelzer, AR; Hemsley, SA; Kraus, MS; Moïse, NS; Rishniw, M, 2010)
"The efficacy of sotalol in the treatment of sustained ventricular arrhythmias has been proved; however, whether its antiarrhythmic effect is due to a beta-blocking activity, a class III antiarrhythmic activity, or a combination of both is not known."	5.08	Metoprolol versus sotalol in the treatment of sustained ventricular tachycardia. ( Antz, M; Cappato, R; Kuck, KH, 1995)
"To evaluate the effects of sotalol in patients with nonsustained ventricular tachyarrhythmia (NSVT)."	5.08	[Brazilian multicenter study of sotalol effectiveness in ventricular arrhythmias]. ( Atie, J; Darwich, R; de Paola, AA; Gizzi, JC; Lorga, AM; Maia, IG; Perez, AK; Rassi, A; Sobral, D, 1996)
"To establish the value of adjuvant dl-sotalol to digoxin for control of the ventricular response in chronic atrial fibrillation, 60 patients were evaluated in a multicenter, randomized, double-blind, parallel, placebo-controlled study."	5.07	Comparative effects of the combination of digoxin and dl-sotalol therapy versus digoxin monotherapy for control of ventricular response in chronic atrial fibrillation. dl-Sotalol Atrial Fibrillation Study Group. ( Bellinger, R; Brodsky, M; Powers, L; Saini, R; Weiss, R; Zoble, R, 1994)
"To evaluate the clinical efficacy of d-sotalol, 84 patients with a history of sustained ventricular tachycardia (VT) or ventricular fibrillation (VF), who had inducible sustained VT/VT at baseline electrophysiologic study (EPS), were investigated after intravenous (IV) d-sotalol (1."	5.07	Acute and chronic antiarrhythmic efficacy of d-sotalol in patients with sustained ventricular tachyarrhythmias. ( Beyer, T; Brachmann, J; Enders, B; Kübler, W; Montero, M; Schöls, W, 1993)
" Arrhythmias for which sotalol was initiated included atrioventricular reciprocating tachycardia/atrioventricular nodal reciprocating tachycardia (n = 105 [55%]), atrial flutter (n = 31 [16%]), ectopic atrial tachycardia (n = 26 [14%]), VT (n = 21 [11%]), and atrial fibrillation (n = 7 [4%])."	3.96	Adverse event rate during inpatient sotalol initiation for the management of supraventricular and ventricular tachycardia in the pediatric and young adult population. ( Abrams, DJ; Alexander, ME; Bevilacqua, LM; Bezzerides, VJ; Chandler, SF; Chu, E; DeWitt, ES; Mah, DY; Triedman, JK; Walsh, EP; Whitehill, RD, 2020)
"Dronedarone was the only anti-arrhythmic drug with significantly lower risk for arrhythmic death, sustained ventricular arrhythmia or ICD implantation than sotalol among patients with atrial fibrillation."	3.88	Ventricular arrhythmia and death among atrial fibrillation patients using anti-arrhythmic drugs. ( Friberg, L, 2018)
"Our objective was to evaluate the efficacy and safety of intravenous (IV) sotalol in the treatment of incessant tachyarrhythmias in children with normal cardiac function."	3.85	Efficacy of Intravenous Sotalol for Treatment of Incessant Tachyarrhythmias in Children. ( Ge, H; Jiang, H; Li, X; Liu, H; Zhang, Y, 2017)
"The effects of d,l-sotalol at therapeutic concentrations (	3.75	d,l-Sotalol at therapeutic concentrations facilitates the occurrence of long-lasting non-stationary reentry during ventricular fibrillation in isolated rabbit hearts. ( Horng, TL; Hsieh, YC; Lin, SF; Lin, TC; Ting, CT; Wu, TJ, 2009)
"We sought to determine the yield of in-hospital monitoring for detection of significant arrhythmia complications in patients starting sotalol therapy for atrial arrhythmias and to identify factors that might predict safe outpatient initiation."	3.70	Is hospital admission for initiation of antiarrhythmic therapy with sotalol for atrial arrhythmias required? Yield of in-hospital monitoring and prediction of risk for significant arrhythmia complications. ( Chung, MK; Jaeger, FJ; Kidwell, GA; Miller, DP; Morant, VA; Niebauer, MJ; Pinski, SL; Schweikert, RA; Tchou, PJ; Trohman, RG; Wilkoff, BL, 1998)
" A total of 152 patients with remote myocardial infarction and documented ventricular tachycardia (VT) or ventricular fibrillation (VF) underwent coronary angiography and programmed ventricular stimulation before and after oral administration of d,l-sotalol (240-640 mg/day)."	3.70	Infarct related artery patency: relation to serial electropharmacological studies and outcome in patients with previous myocardial infarction and ventricular tachyarrhythmias. ( Borggrefe, M; Breithardt, G; Haverkamp, W; Hoppe, UC, 2000)
"To evaluate the antiarrhythmic efficacy of l-sotalol and bisoprolol on inducible ventricular arrhythmias, conscious dogs with 4- to 8-day-old myocardial infarction were studied by programmed electrical stimulation."	3.69	Electrophysiological mechanisms of action of the levorotatory isomer of sotalol in a canine infarct model of inducible ventricular tachycardia: comparison with the beta-1 receptor antagonist bisoprolol. ( Aidonidis, I; Brachmann, J; Hilbel, T; Kuebler, W; Rizos, I, 1994)
"We compared the ability of a new amiodarone-like agent, SR 33589, with that of amiodarone, D,L-sotalol, and lignocaine to reduce the incidence of ventricular fibrillation (VF) and associated arrhythmias caused by acute coronary artery occlusion in anesthetized pigs."	3.69	Effects of a new amiodarone-like agent, SR 33589, in comparison to amiodarone, D,L-sotalol, and lignocaine, on ischemia-induced ventricular arrhythmias in anesthetized pigs. ( Chatelain, P; Finance, O; Manning, A, 1995)
"Implantable cardioverter-defibrillators (ICDs) and d,l-sotalol are widely used to treat ventricular tachyarrhythmia and ventricular fibrillation (VT/VF)."	3.69	Comparison of d,l-sotalol and implantable defibrillators for treatment of sustained ventricular tachycardia or fibrillation in patients with coronary artery disease. ( Block, M; Böcker, D; Borggrefe, M; Breithardt, G; Hammel, D; Haverkamp, W, 1996)
"The efficacy and safety of sotalol therapy for ventricular arrhythmias was evaluated in 133 patients with drug-refractory ventricular arrhythmias."	3.69	Long-term results of electrophysiologically guided sotalol therapy for life-threatening ventricular arrhythmias. ( Epstein, LM; Fitzpatrick, AP; Grogin, HR; Lee, RJ; Lesh, MD; Namekawa-Wong, M; Scheinman, MM; Siu, A; Wong, M, 1996)
"The aim of this study was to assess the antiarrhythmic efficacy and safety of d,l-sotalol in patients with ventricular tachycardia (VT) or ventricular fibrillation (VF) and in survivors of cardiac arrest and to identify the factors that are associated with arrhythmia suppression and therefore might be helpful in predicting drug efficacy."	3.69	Efficacy and safety of d,l-sotalol in patients with ventricular tachycardia and in survivors of cardiac arrest. ( Borggrefe, M; Breithardt, G; Haverkamp, W; Hief, C; Lammers, A; Martinez-Rubio, A; Mühlenkamp, S; Wichter, T, 1997)
"We explored the central hemodynamic responses to oral sotalol during dose titration in patients with ventricular arrhythmias who underwent programmed ventricular stimulation."	3.68	Effect of oral sotalol on systemic hemodynamics and programmed electrical stimulation in patients with ventricular arrhythmias and structural heart disease. ( Deitchman, D; Gomes, JA; Kukin, M; Pe, E; Stewart, D; Winters, SL, 1993)
"The Elimination of Ventricular Premature Beats with Catheter Ablation versus Optimal Antiarrhythmic Drug Treatment (ECTOPIA) trial is a randomized, multicenter, prospective clinical trial to compare the efficacy of catheter ablation versus optimal AAD treatment with sotalol or flecainide/verapamil."	2.94	Elimination of Benign Ventricular Premature Beats or Ventricular Tachycardia with Catheter Ablation versus Two Different Optimal Antiarrhythmic Drug Treatment Regimens (Sotalol or Verapamil/Flecainide). ( Adiyaman, A; Beukema, RJ; de Jong, JSSG; Delnoy, PPHM; Elvan, A; Haanschoten, DM; Khan, M; Otten, AM; Ramdat Misier, AR; Smit, JJJ; Szili-Torok, T; Ter Bekke, RMA; Vernooy, K, 2020)
" Despite careful precautions, serious proarrhythmias, the major limiting side effect of dofetilide, still occurred during long-term follow-up."	2.73	Observations on the safety and effectiveness of dofetilide in patients with paroxysmal atrial fibrillation and normal left ventricular function. ( Bauman, JL; Kehoe, RF; Leal, S; Mykytsey, A; Razminia, M; Saleem, M; Wang, T; Zheutlin, T, 2007)
"Sotalol was rapidly absorbed, with mean peak concentrations occurring 2 to 3 hours after administration."	2.70	Single-dose pharmacokinetics of sotalol in a pediatric population with supraventricular and/or ventricular tachyarrhythmia. ( Cai, B; Epstein, MR; Erickson, CC; Hinderling, PH; Karara, AH; Karpawich, PP; Melikian, AP; Saul, JP; Schaffer, MS; Shi, J, 2001)
" Pharmacokinetic and pharmacodynamic parameters were obtained with standard methods."	2.70	Pharmacokinetics and pharmacodynamics of sotalol in a pediatric population with supraventricular and ventricular tachyarrhythmia. ( Barbey, JT; Beerman, L; Hinderling, PH; Jin, J; Melikian, AP; Ross, B; Saul, JP; Schaffer, MS; Shi, J; Williams, J, 2001)
"In patients prone to sudden cardiac death, there is a reduction in TWA amplitude following the administration of antiadrenergic drugs."	2.70	Effect of metoprolol and d,l-sotalol on microvolt-level T-wave alternans. Results of a prospective, double-blind, randomized study. ( Grönefeld, G; Hohnloser, SH; Klingenheben, T; Li, YG, 2001)
" Adverse events, deemed to be treatment related, were seen in 2."	2.70	A multicentre, double-blind randomized crossover comparative study on the efficacy and safety of dofetilide vs sotalol in patients with inducible sustained ventricular tachycardia and ischaemic heart disease. ( Biffi, M; Borggrefe, M; Boriani, G; Brachmann, J; Butrous, GS; Capucci, A; Kornacewicz-Jack, Z; Lubinski, A; Niederle, R; Wnuk-Wojnar, AM, 2001)
"To derive useful pharmacokinetic (PK) and pharmacodynamic (PD) information for guiding the clinical use of sotalol in pediatric patients with supraventricular (SVT) or ventricular tachyarrhythmia (VT)."	2.70	Population pharmacokinetics and pharmacodynamics of sotalol in pediatric patients with supraventricular or ventricular tachyarrhythmia. ( Gastonguay, MR; Hinderling, PH; Ludden, TM; Melikian, AP; Shi, J, 2001)
"Metoprolol treatment led to a marked reduction in the recurrence of arrhythmic events."	2.69	Comparison of metoprolol and sotalol in preventing ventricular tachyarrhythmias after the implantation of a cardioverter/defibrillator. ( Hauer, B; Schwick, NG; Seidl, K; Senges, J; Zahn, R, 1998)
"D,l-sotalol is an important antiarrhythmic agent to prevent recurrences of sustained ventricular tachyarrhythmias (VT/VF)."	2.69	Suppression of sustained ventricular tachyarrhythmias: a comparison of d,l-sotalol with no antiarrhythmic drug treatment. ( Bosch, RF; Kühlkamp, V; Mermi, J; Mewis, C; Seipel, L, 1999)
"In 22 patients (group II) sustained ventricular tachycardia remained inducible during D,L-sotalol treatment."	2.69	Predicting the effect of D,L-sotalol on ventricular tachycardia inducibility from the RR variability response. ( Beurrier, D; Brembilla-Perrot, B; Claudon, O; Houriez, P; Preiss, JP, 1999)
"Well-tolerated ventricular tachycardia in patients with structural heart disease does not carry a significantly better prognosis than ventricular tachyarrhythmia with more severe hemodynamic consequences."	2.69	Determinants of outcome in patients with sustained ventricular tachyarrhythmias: the antiarrhythmics versus implantable defibrillators (AVID) study registry. ( Cook, JR; Epstein, AE; Greene, HL; Jadonath, R; Lancaster, S; Marinchak, RA; Pacifico, A; Pinski, SL; Yao, Q, 2000)
"A group of 57 patients with ischemic heart disease and inducible ventricular tachycardia (VT) at electrophysiological study (EPS) were selected from a population enrolled in a randomized double-blind crossover study of dofetilide (500 micrograms bid) versus sotalol (160 mg bid)."	2.69	Repolarization changes in a double-blind crossover study of dofetilide versus sotalol in the treatment of ventricular tachycardia. ( Bacchi, L; Biffi, M; Bitonti, F; Boriani, G; Branzi, A; Butrous, G; De Simone, N; Martignani, C; Zannoli, R, 2000)
"Its precise effect on the prevention of ventricular tachycardia-ventricular fibrillation (VTVF) compared to class I agents has not been evaluated in a blinded study."	2.68	Multicenter trial of sotalol compared with procainamide in the suppression of inducible ventricular tachycardia: a double-blind, randomized parallel evaluation. Sotalol Multicenter Study Group. ( Kehoe, R; Quart, B; Scheinman, M; Singh, BN; Woosley, RL, 1995)
"Patients with ventricular tachycardia also had either syncope or other serious cardiac symptoms, along with a left ventricular ejection fraction of 0."	2.68	A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. ( , 1997)
" Two schedules of dosing were tested: 3 x 80 mg and 2 x 160 mg during 28 days of therapy."	2.68	[Evaluation of antiarrhythmic efficacy of sotalol in various doses in patients with ventricular tachyarrhythmias]. ( Dabrowski, R; Gasior, Z; Jasek, S; Kowalik, I; Luczak, D; Matar, A; Skrabucha, B; Stanke, A; Szwed, H, 1997)
"Sotalol was significantly more efficacious in preventing recurrences, arrhythmic mortality, cardiac mortality, and total mortality than the other agents and it was better tolerated."	2.67	Results of Holter ECG guided therapy for ventricular arrhythmias: the ESVEM trial. ( Lazzara, R, 1994)
"Overall efficacy of ventricular tachycardia pace termination was 69% and the time required to stop ventricular tachycardia was 14."	2.67	Randomized cross-over evaluation of two adaptive pacing algorithms for the termination of ventricular tachycardia. ( Green, MS; Kantoch, MJ; Tang, AS, 1993)
"Sotalol was effective in control of VT, mainly the MRVT."	2.67	[Efficacy of sotalol in idiopathic ventricular arrhythmia originating in the right ventricular outflow tract]. ( Alves, PA; Costa, AM; Magalhães Júnior, A; Maia, IG; Peres, AK; Sá, R; Seixas, TN, 1994)
"Sotalol was significantly more effective than lignocaine whether analysed on an intention-to-treat basis (69% vs 18%; 95% confidence interval for absolute difference of 51% 22-80%, p = 0."	2.67	Double-blind trial of lignocaine versus sotalol for acute termination of spontaneous sustained ventricular tachycardia. ( Ho, DS; Richards, DA; Ross, DL; Uther, JB; Zecchin, RP, 1994)
"The sotalol dose was titrated to 240 mg twice daily over 7 days."	2.67	Electrophysiologic effects of sotalol and amiodarone in patients with sustained monomorphic ventricular tachycardia. ( Bakr, O; Daoud, E; Hummel, JD; Kou, W; Man, KC; Morady, F; Niebauer, M; Strickberger, SA; Williamson, BD, 1994)
"486 patients with documented ventricular tachycardia or resuscitated sudden death were randomized to EPS (n = 242) or HM (n = 244) and underwent serial drug testing with up to six antiarrhythmics; in the EPS limb a drug efficacy prediction was achieved in 108 patients (45%), compared to 188 (77%) in the HM limb (P < 0."	2.67	Comparative efficacy of sotalol and class I antiarrhythmic agents in patients with ventricular tachycardia or fibrillation: results of the Electrophysiology Study Versus Electrocardiographic Monitoring (ESVEM) Trial. ( Klein, RC, 1993)
"Sotalol was discontinued because of adverse effects in 42 (8."	2.67	Safety and efficacy of oral sotalol for sustained ventricular tachyarrhythmias refractory to other antiarrhythmic agents. ( Dunnington, C; Ezri, MD; Kehoe, RF; Lueken, M; MacNeil, DJ; Nazari, J; Spangenberg, RB; Zheutlin, TA, 1993)
"This study assessed the efficacy of the combination of sotalol and either quinidine or procainamide in preventing sustained ventricular tachycardia inducibility and recurrence and prospectively evaluated the ability of the drug combination to prevent ventricular tachycardia recurrence when the arrhythmia remained inducible but was modified."	2.67	Sotalol and type IA drugs in combination prevent recurrence of sustained ventricular tachycardia. ( Berman, N; Dorian, P; Hardy, J; Mitchell, J; Newman, D, 1993)
"Prevention of ventricular tachycardia (VT) recurrence with the use of antiarrhythmic drugs or catheter ablation may be warranted."	2.55	Ventricular Tachycardia with ICD Shocks: When to Medicate and When to Ablate. ( AbdelWahab, A; Sapp, J, 2017)
"Amiodarone is a highly efficacious antiarrhythmic agent for many cardiac arrhythmias, ranging from atrial fibrillation to malignant ventricular tachyarrhythmias, and seems to be superior to other antiarrhythmic agents."	2.42	Arrhythmias in the intensive care patient. ( Brandts, B; Trappe, HJ; Weismueller, P, 2003)
"Sotalol was approved for treatment of atrial fibrillation and atrial flutter (AF)."	2.42	Oral class III antiarrhythmics: what is new? ( Khan, MH, 2004)
"Drugs can cause cardiac arrhythmias in a number of clinical situations, and many of the implicated agents are used to treat non-cardiac conditions."	2.40	Drug-induced cardiac arrhythmias: incidence, prevention and management. ( Doig, JC, 1997)
"Patients with symptomatic ventricular tachycardia, ventricular fibrillation, or aborted sudden cardiac death remain at high risk for arrhythmia recurrence."	2.40	Drugs versus devices in controlling ventricular tachycardia, ventricular fibrillation, and recurrent cardiac arrest. ( Borggrefe, M; Breithardt, G; Eckardt, L; Haverkamp, W, 1997)
"Sotalol's ability to suppress ventricular ectopy is similar to that of class I agents and better than that of standard beta-blockers."	2.40	Sotalol: An important new antiarrhythmic. ( Anderson, JL; Prystowsky, EN, 1999)
"Pharmacological therapy of cardiac arrhythmias continues to evolve, with an increasing shift from class I to class III compounds and beta-blockers."	2.39	Class III antiarrhythmic drugs. ( Ahmed, R; Singh, BN, 1994)
"Sotalol is a novel antiarrhythmic agent combining beta-adrenergic-antagonist actions with the ability to increase cardiac repolarization and refractoriness."	2.39	Sotalol. ( Hohnloser, SH; Woosley, RL, 1994)
"Sotalol is a unique compound with several potential antiarrhythmic mechanisms, including beta blockade (class II activity), action potential duration prolongation (class III activity), and possibly reduction of QT dispersion."	2.39	Evolving role of sotalol in the management of ventricular tachyarrhythmias. ( McGovern, BA; O'Callaghan, PA, 1996)
"sustained ventricular tachycardia, ventricular fibrillation, aborted sudden cardiac death) are changing."	2.39	[Pharmacologic therapy of ventricular tachyarrhythmias: value of class III anti-arrhythmia drugs]. ( Block, M; Böcker, D; Borggrefe, M; Breithardt, G; Haverkamp, W, 1996)
"Amiodarone has been demonstrated to be an important and effective antiarrhythmic agent, as has sotalol."	2.38	Empiric use of amiodarone and sotalol. ( Nora, M; Zipes, DP, 1993)
"Sotalol is a unique antiarrhythmic drug that combines beta-blocking effects with actions to prolong action potential duration."	2.38	Practical considerations in the use of sotalol for ventricular tachycardia and ventricular fibrillation. ( Campbell, RW; Furniss, SS, 1993)
"Sotalol is a unique beta-blocker that prolongs repolarization."	2.38	Efficacy and safety of sotalol in patients with complex ventricular arrhythmias. ( Hohnloser, SH; Just, H; Klingenheben, T; van de Loo, A; Zabel, M, 1992)
"This study suggests that flecainide and beta-blockers association is complementary to implantable cardioverter-defibrillator and catheter ablation and is safe for treating persistent symptomatic VA in patients with ARVC."	1.72	Safety and efficacy of flecainide associated with beta-blockers in arrhythmogenic right ventricular cardiomyopathy. ( Badenco, N; Duthoit, G; Frank, R; Gandjbakhch, E; Hidden-Lucet, F; Himbert, C; Laredo, M; Maupain, C; Rolland, T; Waintraub, X, 2022)
" A medication episode was defined as a timeframe in which the highest dosage at a fixed level of a single drug was used in a patient."	1.62	The Efficacy of Anti-Arrhythmic Drugs in Children With Idiopathic Frequent Symptomatic or Asymptomatic Premature Ventricular Complexes With or Without Asymptomatic Ventricular Tachycardia: a Retrospective Multi-Center Study. ( Bertels, RA; Blom, NA; Filippini, LH; Kammeraad, JAE; Knobbe, I; Kuipers, IM; Zeelenberg, AM, 2021)
"Ivabradine treatment resulted in occurrence of EAD and polymorphic VT in 9 of 12 sotalol-treated hearts (212 episodes), and 8 of 12 veratridine-treated hearts (155 episodes)."	1.51	Ivabradine Aggravates the Proarrhythmic Risk in Experimental Models of Long QT Syndrome. ( Dechering, DG; Eckardt, L; Ellermann, C; Frommeyer, G; Kochhäuser, S; Lange, PS; Leitz, P; Weller, J, 2019)
"IV sotalol is an effective antiarrhythmic option for pediatric patients and may be an excellent agent for acute termination of active arrhythmias."	1.48	Early experience with intravenous sotalol in children with and without congenital heart disease. ( Asaki, SY; de la Uz, CM; Kim, JJ; Lam, WW; Landstrom, AP; Miyake, CY; Niu, MC; Patel, R; Rusin, CG; Schneider, AE; Valdés, SO, 2018)
"We present a case of ventricular tachycardia with clinical features suggestive of arrhythmogenic right ventricular cardiomyopathy."	1.38	Cardiac sarcoidosis masquerading as arrhythmogenic right ventricular cardiomyopathy. ( Chia, PL; Kuchar, D; Subbiah, RN; Walker, B, 2012)
"Duration of ventricular tachycardia (VT) episodes was reduced from 15."	1.37	First direct comparison of the late sodium current blocker ranolazine to established antiarrhythmic agents in an ischemia/reperfusion model. ( Bhandari, A; Dow, JS; Kloner, RA, 2011)
"Arrhythmogenic right ventricular cardiomyopathy is a desmosomal disease."	1.37	Guidelines for the diagnosis and management of arrhythmogenic right ventricular cardiomyopathy. ( Smith, W, 2011)
"Ranolazine is a drug that exerts antianginal and antiischemic effects and also acts as an antiarrhythmic in isolation and in combination with other class III medications."	1.37	Ranolazine reduces ventricular tachycardia burden and ICD shocks in patients with drug-refractory ICD shocks. ( Anderson, JL; Bair, TL; Bunch, TJ; Crandall, BG; Day, JD; Lappe, DL; Mader, KM; Mahapatra, S; May, HT; Molden, J; Muhlestein, JB; Murdock, D; Osborn, JS; Weiss, JP, 2011)
"As the population ages, recurrent ventricular tachycardia (VT) is increasingly encountered in elderly patients with ischemic heart disease."	1.36	Mortality and safety of catheter ablation for antiarrhythmic drug-refractory ventricular tachycardia in elderly patients with coronary artery disease. ( Inada, K; Koplan, BA; Roberts-Thomson, KC; Seiler, J; Steven, D; Stevenson, WG; Tedrow, UB, 2010)
"Sotalol was associated with a greater risk of any clinically relevant ventricular arrhythmia as defined by sustained ventricular tachycardia or ICD therapy (hazard ratio [HR]: 2."	1.35	Efficacy of antiarrhythmic drugs in arrhythmogenic right ventricular cardiomyopathy: a report from the North American ARVC Registry. ( Cannom, DS; Estes, NA; Glidden, DV; Marcus, F; Marcus, GM; Polonsky, B; Scheinman, MM; Smith, LM; Zareba, W, 2009)
"Sotalol was administered to 57 patients, and its efficacy was assessed by EPS."	1.33	Electrophysiologic study-guided therapy with sotalol for life-threatening ventricular tachyarrhythmias. ( Aizawa, Y; Chinushi, M; Fujita, S; Furushima, H; Hirono, T; Hosaka, Y; Kato, K; Komura, S; Sugiura, H; Tanabe, Y; Washizuka, T; Watanabe, H, 2005)
"Two patients presented with ventricular tachycardia and one had an atrioventricular re-entrant tachycardia."	1.33	Tachycardia-induced elevations in cardiac troponin in the absence of coronary artery disease. ( Cruz, L; Hong, R; Yeo, KK, 2006)
"Prior to polymorphic ventricular tachycardia, dispersion of APD further increased (APD70max-min: 17 +/- 3 ms; APD90max-min: 25 +/- 3 ms; p < 0."	1.32	Prolonged action potential durations, increased dispersion of repolarization, and polymorphic ventricular tachycardia in a mouse model of proarrhythmia. ( Breithardt, G; Eckardt, L; Fabritz, L; Franz, MR; Haverkamp, W; Kirchhof, P; Milberg, P; Mönnig, G, 2003)
"Cardiac mortality and sudden cardiac death rates also were higher in group 3 patients."	1.32	Clinical usefulness of electrophysiologic testing in patients with ventricular tachycardia and chronic chagasic cardiomyopathy treated with amiodarone or sotalol. ( de Paola, AA; Fenelon, G; Friedman, PA; Leite, LR; Silva, GG; Simoes, A, 2003)
"Sustained ventricular tachycardia was induced by programmed stimulation in dogs 4 days after left anterior coronary artery occlusion and reentrant circuits in the epicardial border zone (EBZ) mapped."	1.32	Beta receptor blockade potentiates the antiarrhythmic actions of d-sotalol on reentrant ventricular tachycardia in a canine model of myocardial infarction. ( Cabo, C; Coromilas, J; Kassotis, J; Sauberman, RB; Wit, AL, 2003)
"D,l sotalol is an antiarrhythmic widely used for treating ventricular excitability, especially ventricular tachycardia (VT)."	1.31	[Action of sotalol on high-amplification electrocardiogram]. ( Beurrier, D; Brembilla-Perrot, B; Claudon, O; Houriez, P; Louis, P; Preiss, JP; Terrier de la Chaise, A, 2000)
"Sustained ventricular tachycardia (VT) can be unstable, can be associated with serious symptoms, or can be stable and relatively free of symptoms."	1.31	"Stable" ventricular tachycardia is not a benign rhythm : insights from the antiarrhythmics versus implantable defibrillators (AVID) registry. ( Epstein, AE; Hallstrom, AP; Jadonath, RL; Lancaster, SE; McAnulty, JH; Mounsey, P; Raitt, MH; Renfroe, EG; Steinberg, JS, 2001)
" The mechanisms underlying the efficacy of this drug combination have not been fully elucidated."	1.30	Electrophysiologic mechanisms of antiarrhythmic efficacy of a sotalol and class Ia drug combination: elimination of reverse use dependence. ( Dorian, P; Ham, M; Lee, SD; Newman, D, 1997)
"Recurrence rates of ventricular tachyarrhythmias are high despite complete suppression of the arrhythmia during programmed stimulation."	1.30	Efficacy and proarrhythmia with the use of d,l-sotalol for sustained ventricular tachyarrhythmias. ( Kühlkamp, V; Mermi, J; Mewis, C; Seipel, L, 1997)
"Treatment with sotalol exacerbated his symptoms and resulted in recurrent polymorphic ventricular tachycardia with a pattern indistinguishable from that caused by a class III action."	1.30	Sotalol associated polymorphic ventricular tachycardia and coronary spasm. ( Grace, AA; Lowe, MD; Stone, DL, 1998)
"Isoproterenol was administered as a loading dosage of 0."	1.30	Use-dependent electrophysiologic effects of DL-sotalol and modulation by isoproterenol in the human ventricle. ( Aizawa, Y; Furushima, H; Naitoh, N; Ohira, K; Taneda, K, 1998)
"Polymorphic ventricular tachycardias (PVT) occur spontaneously in canine hearts under the combination of D-sotalol (S), bradycardia and phenylephrine (PE)."	1.30	Polymorphic ventricular tachycardias induced by D-sotalol and phenylephrine in canine preparations of atrioventricular block: initiation in the conduction system followed by spatially unstable re-entry. ( Brunet, S; Cardinal, R; Derakhchan, K; Klug, D; Kuś, T; Pharand, C; Sasyniuk, BI, 1998)
"Thirty patients with VT/VF (age: 57+/-11 years, 20 patients with coronary heart disease, 7 patients with no structural heart disease, 3 with others) and reproducible induction of VT/VF (28 patients VT, two patients VF) in a baseline PVS, were suppressible with sotalol (mean dosage 395+/-137 mg) in a subsequent PVS."	1.30	Long-term reproducibility of electrophysiologically guided therapy with sotalol in patients with ventricular tachyarrhythmias. ( Bosch, RF; Kühlkamp, V; Mermi, J; Mewis, C; Seipel, L, 1999)
" This patient was managed with a reduction in the dosage and with a regimen of digoxin and furosemide."	1.30	[Effect of sotalol on systemic hemodynamics and electrophysiology in patients with life-threatening ventricular tachyarrhythmias]. ( Fu, G; Shan, J; Wille, B, 1999)
"d-Sotalol was less effective in the dilated left ventricle, narrowing the excitable gap only 9%, a difference that was not statistically significant."	1.29	Interaction of acute ventricular dilatation and d-sotalol during sustained reentrant ventricular tachycardia around a fixed obstacle. ( Allessie, MA; Boersma, L; Kirchhof, CJ; Reiter, MJ; Zetelaki, Z, 1994)
"Sotalol was administered to 32 patients with a mean age of 8."	1.29	[Results of oral sotalol therapy in children with supraventricular and ventricular arrhythmias]. ( Kallfelz, HC; Lehmann, C; Paul, T; Pfammatter, JP, 1994)
"Sotalol is an antiarrhythmic medication that has properties of both a beta-blocker and a class III agent and has been used safely and effectively to treat arrhythmias of multiple mechanisms in pediatric patients."	1.29	Sotalol for refractory arrhythmias in pediatric and young adult patients: initial efficacy and long-term outcome. ( Lulu, JA; Saul, JP; Tanel, RE; Walsh, EP, 1995)
"Mexiletine was recently shown to antagonize the effects of sotalol on repolarization of canine Purkinje fibers."	1.29	Antiarrhythmic effect of a sotalol-mexiletine combination on induced ventricular tachycardia in dogs. ( Cheymol, G; Chézalviel, F; Davy, JM; Guhennec, C; Jagueux, M; Poirier, JM; Simandoux, V; Vernhet, L; Weissenburger, J, 1993)
"Slowing of ventricular tachycardia rate and changes in morphology may have implications in patients receiving implantable cardioverter-defibrillators or those undergoing ablative procedures."	1.29	Clinical implications of pleomorphic ventricular tachycardias on oral sotalol therapy. ( Borggrefe, M; Breithardt, G; Chen, X; Haverkamp, W; Hindricks, G; Lubinski, A; Reisinger, J; Shenasa, M, 1995)
"Undersensing of ventricular tachyarrhythmias is a potentially serious problem, as it may lead to failure to deliver therapy."	1.29	Undersensing during ventricular tachyarrhythmias in a third-generation implantable cardioverter defibrillator: diagnosis using stored electrograms and correction with programming. ( Damle, RS; Kelly, PA; Mann, DE; Reiter, MJ, 1994)
"Sotalol is a class III antiarrhythmic drug with additional beta-blocker activity that has been shown to be effective in supraventricular and ventricular arrhythmias."	1.29	Efficacy of sotalol guided by programmed electrical stimulation for sustained ventricular arrhythmias secondary to coronary artery disease. ( Boone, J; Kerr, CR; Mohama, R; Yeung-Lai-Wah, JA; Young, GD, 1994)
"Sotalol dose was not appropriately adjusted for creatinine clearance which is age and gender dependent."	1.29	Sotalol proarrhythmia: a report of five cases and an audit of the use of a sotalol in a teaching hospital. ( Basta, MN; Fletcher, PJ; Leitch, JW, 1996)
"Occurrence rates of arrhythmias treated with drugs tested for efficacy either by suppression of inducible arrhythmias or by suppression of spontaneous ectopy were higher and equivalent for both testing methods."	1.29	From first class to third class: recent upheaval in antiarrhythmic therapy--lessons from clinical trials. ( Lazzara, R, 1996)
"In patients in whom the ventricular tachycardia could be induced despite oral application of d/l sotalol, control of the ventricular tachyarrhythmia was attempted by the use of sotalol in combination with mexiletine (n = 2), amiodarone (n = 9), catheter ablation (n = 2), antitachycardia surgery (n = 1) or the implantation of an automatic cardioverter defibrillator (n = 12)."	1.29	Long-term efficacy of d/l sotalol in patients with sustained ventricular tachycardia refractory to class I antiarrhythmic drugs. ( Braun, U; Kühlkamp, V; Mermi, J; Mewis, C; Seipel, L, 1995)
"On sotalol, VT was initiated in only one."	1.28	Dual chamber rate responsive pacing to allow sotalol therapy for ventricular tachycardia. ( Davis, MJ; Horrigan, MC; May, C; Smith, P, 1992)

Research

Studies (191)

Authors

Clinical Trials (4)

Trial Overview

Trial Outcomes

Cardiovascular Hospitalizations

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	114 (59.69)	18.2507
2000's	49 (25.65)	29.6817
2010's	21 (10.99)	24.3611
2020's	7 (3.66)	2.80

Authors	Studies
Rolland, T	1
Badenco, N	1
Maupain, C	1
Duthoit, G	1
Waintraub, X	1
Laredo, M	1
Himbert, C	1
Frank, R	1
Hidden-Lucet, F	1
Gandjbakhch, E	1
Valderrábano, M	1
Kiani, S	1
Sayegh, MN	1
Ibrahim, R	1
Bhatia, NK	1
Merchant, FM	1
Shah, AD	1
Westerman, SB	1
De Lurgio, DB	1
Patel, AM	1
Thompkins, CM	1
Leon, AR	1
Lloyd, MS	1
El-Chami, MF	1
Chandler, SF	1
Chu, E	1
Whitehill, RD	1
Bevilacqua, LM	1
Bezzerides, VJ	1
DeWitt, ES	1
Alexander, ME	1
Abrams, DJ	1
Triedman, JK	1
Walsh, EP	2
Mah, DY	1
Shiohira, S	1
Kawabata, M	1
Goya, M	1
Maeda, S	1
Sasano, T	1
Hirao, K	1
Haanschoten, DM	1
Vernooy, K	1
Beukema, RJ	1
Szili-Torok, T	1
Ter Bekke, RMA	1
Khan, M	1
de Jong, JSSG	1
Otten, AM	1
Adiyaman, A	1
Smit, JJJ	1
Delnoy, PPHM	1
Ramdat Misier, AR	1
Elvan, A	1
Bertels, RA	1
Kammeraad, JAE	1
Zeelenberg, AM	1
Filippini, LH	1
Knobbe, I	1
Kuipers, IM	1
Blom, NA	1
Pokorney, SD	1
Mi, X	1
Hammill, BG	1
Allen LaPointe, NM	1
Curtis, LH	1
Al-Khatib, SM	1
AbdelWahab, A	1
Sapp, J	1
Valdés, SO	1
Miyake, CY	1
Niu, MC	1
de la Uz, CM	1
Asaki, SY	1
Landstrom, AP	1
Schneider, AE	1
Rusin, CG	1
Patel, R	1
Lam, WW	1
Kim, JJ	1
Friberg, L	1
Frommeyer, G	2
Weller, J	1
Ellermann, C	1
Leitz, P	1
Kochhäuser, S	1
Lange, PS	1
Dechering, DG	1
Eckardt, L	4
Sanders, RA	1
Kurosawa, TA	1
Ermakov, S	1
Hoffmayer, KS	1
Gerstenfeld, EP	2
Scheinman, MM	3
Franz, MR	2
Gray, RA	1
Karasik, P	1
Moore, HJ	1
Singh, SN	1
Conte, G	1
Sieira, J	1
Ciconte, G	1
de Asmundis, C	1
Chierchia, GB	1
Baltogiannis, G	1
Di Giovanni, G	1
La Meir, M	1
Wellens, F	1
Czapla, J	1
Wauters, K	1
Levinstein, M	1
Saitoh, Y	1
Irfan, G	1
Julià, J	1
Pappaert, G	1
Brugada, P	1
Ito, S	1
Stout, KK	1
Robinson, MR	1
Long, B	1
Koyfman, A	1
Li, X	1
Zhang, Y	2
Liu, H	1
Jiang, H	1
Ge, H	1
Mitchell, LB	2
Maeda, K	1
Takagi, M	1
Tatsumi, H	1
Nakagawa, E	1
Yoshiyama, M	1
Hsieh, YC	1
Horng, TL	1
Lin, SF	1
Lin, TC	1
Ting, CT	1
Wu, TJ	1
Bestetti, R	1
Cardinalli-Neto, A	1
Srivastava, A	1
Khan, MA	1
Watkiss, J	1
Marcus, GM	1
Glidden, DV	1
Polonsky, B	1
Zareba, W	1
Smith, LM	1
Cannom, DS	1
Estes, NA	1
Marcus, F	1
Gilewski, W	1
Bednarska, D	1
Sinkiewicz, W	1
Shimada, YJ	1
Sato, K	1
Hanon, S	1
Schweitzer, P	1
Inada, K	1
Roberts-Thomson, KC	1
Seiler, J	1
Steven, D	1
Tedrow, UB	1
Koplan, BA	1
Stevenson, WG	2
Winter, RL	1
Hariu, CD	1
Saunders, AB	1
Gelzer, AR	1
Kraus, MS	1
Rishniw, M	1
Hemsley, SA	1
Moïse, NS	1
Dizon, J	1
Chen, K	1
Dizon, S	1
Biviano, A	1
Whang, W	1
Ehlert, F	1
Vazquez, J	1
Nazif, T	1
Garan, H	2
Kloner, RA	1
Dow, JS	1
Bhandari, A	1
Smith, W	1
Bunch, TJ	1
Mahapatra, S	1
Murdock, D	1
Molden, J	1
Weiss, JP	1
May, HT	1
Bair, TL	1
Mader, KM	1
Crandall, BG	1
Day, JD	1
Osborn, JS	1
Muhlestein, JB	1
Lappe, DL	1
Anderson, JL	2
Chia, PL	1
Subbiah, RN	1
Kuchar, D	1
Walker, B	1
Milberg, P	2
Pott, C	1
Fink, M	1
Ruhe, M	1
Matsuda, T	1
Baba, A	1
Klocke, R	1
Quang, TH	1
Nikol, S	1
Stypmann, J	1
Osada, N	1
Müller, FU	1
Breithardt, G	11
Noble, D	1
Spivack, C	1
Fabritz, L	1
Kirchhof, P	1
Mönnig, G	1
Haverkamp, W	8
Kettering, K	1
Mewis, C	5
Dörnberger, V	1
Vonthein, R	1
Bosch, RF	3
Kühlkamp, V	5
Naik, N	1
Talwar, KK	1
Leite, LR	1
Fenelon, G	1
Simoes, A	1
Silva, GG	1
Friedman, PA	1
de Paola, AA	2
Exner, DV	1
Klein, GJ	1
Trappe, HJ	1
Brandts, B	1
Weismueller, P	1
Kassotis, J	1
Sauberman, RB	1
Cabo, C	1
Wit, AL	1
Coromilas, J	1
Khan, MH	1
Muto, S	1
Ashizawa, N	1
Arakawa, S	1
Tanaka, K	1
Komiya, N	1
Toda, G	1
Seto, S	1
Yano, K	1
Rajawat, YS	1
Patel, VV	1
Nayak, H	1
Marchlinski, FE	1
Watanabe, H	2
Chinushi, M	5
Washizuka, T	4
Sugiura, H	2
Hirono, T	2
Komura, S	3
Hosaka, Y	2
Tanabe, Y	3
Furushima, H	5
Fujita, S	1
Kato, K	1
Aizawa, Y	8
Kowey, PR	2
Yan, GX	2
Shukla, G	1
Chaudhry, GM	1
Orlov, M	1
Hoffmeister, P	1
Haffajee, C	1
Yeo, KK	1
Cruz, L	1
Hong, R	1
Mykytsey, A	1
Bauman, JL	1
Razminia, M	1
Zheutlin, T	1
Wang, T	1
Saleem, M	1
Leal, S	1
Kehoe, RF	2
Okamura, K	1
Sato, A	1
Izumi, D	1
Reiffel, JA	3
Patterson, E	1
Scherlag, BJ	1
Lazzara, R	3
Garrison, GL	1
Berlin, KD	1
Reiter, MJ	3
Zetelaki, Z	1
Kirchhof, CJ	1
Boersma, L	2
Allessie, MA	1
Martínez-Rubio, A	3
Shenasa, M	2
Chen, X	2
Wichter, T	2
Borggrefe, M	9
Singer, I	1
Cui, G	1
Sen, L	1
Sager, P	1
Uppal, P	1
Singh, BN	3
Paul, T	1
Lehmann, C	1
Pfammatter, JP	1
Kallfelz, HC	1
Tanel, RE	1
Lulu, JA	1
Saul, JP	3
Bode-Böger, SM	1
Böger, RH	1
Frölich, JC	1
Hoffmann, E	2
Mattke, S	1
Haberl, R	1
Steinbeck, G	1
Chézalviel, F	1
Weissenburger, J	1
Guhennec, C	1
Jagueux, M	1
Davy, JM	1
Vernhet, L	1
Simandoux, V	1
Poirier, JM	1
Cheymol, G	1
Hohnloser, SH	6
Zabel, M	2
Just, H	2
Raeder, EA	1
Berman, ND	1
Dorian, P	5
Kantoch, MJ	1
Green, MS	1
Tang, AS	1
Pool, PE	1
Seagren, SC	1
Salel, AF	1
Biblo, LA	1
Carlson, MD	1
Waldo, AL	1
Winters, SL	2
Curwin, JH	1
Reisinger, J	1
Lubinski, A	2
Hindricks, G	2
Kehoe, R	1
Woosley, RL	2
Scheinman, M	1
Quart, B	1
Janssen, JH	1
Maia, IG	2
Seixas, TN	1
Costa, AM	1
Peres, AK	1
Magalhães Júnior, A	1
Sá, R	1
Alves, PA	1
Hallstrom, AP	2
Greene, HL	3
Wyse, DG	1
Zipes, D	1
Epstein, AE	3
Domanski, MJ	1
Schron, EB	1
Aliot, E	1
Sadoul, N	1
De Chillou, C	1
Ho, DS	1
Zecchin, RP	1
Richards, DA	1
Uther, JB	3
Ross, DL	3
Aidonidis, I	1
Rizos, I	1
Hilbel, T	2
Kuebler, W	1
Brachmann, J	5
Man, KC	1
Williamson, BD	1
Niebauer, M	1
Daoud, E	1
Bakr, O	1
Strickberger, SA	1
Hummel, JD	1
Kou, W	1
Morady, F	1
Mann, DE	1
Kelly, PA	1
Damle, RS	1
Klingenheben, T	3
Brugada, J	1
Abdollah, H	1
Kirchhof, C	1
Allessie, M	1
Brodsky, M	1
Saini, R	1
Bellinger, R	1
Zoble, R	1
Weiss, R	1
Powers, L	1
Young, GD	1
Kerr, CR	1
Mohama, R	1
Boone, J	1
Yeung-Lai-Wah, JA	1
Gutiérrez-Larraya, F	1
Jabón, A	1
Galatius-Jensen, S	1
Clemmensen, PM	1
Pietersen, AH	1
Nielsen, HV	1
Ahmed, R	1
Dunnington, CS	1
Höher, M	1
Axmann, J	1
Eggeling, T	1
Kochs, M	1
Weismüller, P	1
Hombach, V	1
Makkar, RR	1
Fromm, BS	1
Steinman, RT	1
Meissner, MD	1
Lehmann, MH	1
Nora, M	1
Zipes, DP	1
Klein, RC	1
Schöls, W	2
Beyer, T	2
Montero, M	1
Enders, B	1
Kübler, W	2
Kukin, M	1
Pe, E	1
Stewart, D	1
Deitchman, D	1
Gomes, JA	1
MacNeil, DJ	1
Zheutlin, TA	1
Ezri, MD	1
Nazari, J	1
Spangenberg, RB	1
Dunnington, C	1
Lueken, M	1
Campbell, RW	1
Furniss, SS	1
Leibowitz, D	1
Newman, D	4
Berman, N	1
Hardy, J	1
Mitchell, J	2
Holcomb, SS	1
Brooks, MM	1
Hallstrom, A	1
Peckova, M	1
Finance, O	1
Manning, A	1
Chatelain, P	1
Antz, M	1
Cappato, R	1
Kuck, KH	1
Shimizu, W	1
Kurita, T	1
Suyama, K	1
Aihara, N	1
Kamakura, S	1
Shimomura, K	1
Böcker, D	3
Block, M	4
Hammel, D	1
Millar, RS	1
Cohen, MB	1
Snow, JS	1
Merkatz, KA	1
Kholwadwala, D	1
Jadonath, RL	2
Goldner, BG	1
Cohen, TJ	1
van Hemel, NM	1
Kingma, JH	1
Defauw, JJ	1
Hoogteijling-van Dusseldorp, E	1
Kelder, JC	1
Beukema, WP	1
Vermeulen, FE	1
Basta, MN	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
[NCT00000531]	Phase 3	0 participants	Interventional	1992-09-30	Completed
[NCT00000518]	Phase 3	0 participants	Interventional	1985-07-31	Completed
Catheter Ablation for Ventricular Tachycardia in Patients With an Implantable Cardioverter Defibrillator (CALYPSO) PILOT TRIAL[NCT01576042]		27 participants (Actual)	Interventional	2012-05-31	Terminated (stopped due to Main objectives of the study were met; consensus among investigators that continuing the study would not add new information beyond that already learned.)
Effects of Surgical Monopolar Electrocautery and Optimal Electrosurgery Unit Return Pad Placement on Implantable Cardioverter Defibrillators Protocol[NCT01572246]		167 participants (Actual)	Observational	2012-05-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Records participants hospitalized for VT during the study (NCT01576042)
Timeframe: Baseline, 6 months

Number of Participants Completed Month 3 Follow-Up

Intervention	participants (Number)
Catheter Ablation	5
Antiarrhythmic Medication	7

Records participants who completed Month 3 Follow-Up Visit (NCT01576042)
Timeframe: 3 months

Number of Participants Completed Month 6 Follow-Up

Intervention	participants (Number)
Catheter Ablation	11
Antiarrhythmic Medication	12

Records participants who completed Month 6 Follow-Up Visit (NCT01576042)
Timeframe: 6 Months

Number of Participants Had at Least One of the Efficacy Outcome Measurement

Intervention	participants (Number)
Catheter Ablation	7
Antiarrhythmic Medication	10

Records participants who had at least one of the efficacy outcome measurement (including death, hospitalization due to VT) (NCT01576042)
Timeframe: 6 Months

Number of Participants Received Treatment Assigned

Intervention	participants (Number)
Catheter Ablation	11
Antiarrhythmic Medication	14

Records participants who received study randomized treatment during the study (NCT01576042)
Timeframe: 6 months

Number of Participants Remained on Randomized Treatment Assignment

Intervention	participants (Number)
Catheter Ablation	11
Antiarrhythmic Medication	14

Records participants who only received study treatment as randomized during the entire study (NCT01576042)
Timeframe: 6 month

Number of Participants Switched to Other Arm

Intervention	participants (Number)
Catheter Ablation	6
Antiarrhythmic Medication	13

Records participants who received study treatment as randomized and later switched to other treatment arm during the study (NCT01576042)
Timeframe: 6 months

Time to First Recurrent ICD Therapy for VT

Intervention	participants (Number)
Catheter Ablation	5
Antiarrhythmic Medication	1

Days from the date of the first study treatment to the date of first ICD recurrent therapy for VT. (NCT01576042)
Timeframe: Baseline, 6 months

Reviews

31 reviews available for sotalol and Atrioventricular Nodal Re-Entrant Tachycardia

Trials

45 trials available for sotalol and Atrioventricular Nodal Re-Entrant Tachycardia

Other Studies

116 other studies available for sotalol and Atrioventricular Nodal Re-Entrant Tachycardia

Article	Year
The Future of Antiarrhythmic Drug Therapy: Will Drugs Be Entirely Replaced by Procedures? Methodist DeBakey cardiovascular journal, 2022, Volume: 18, Issue:5 Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Catheter Ablation; Humans; Sotalol; Tachycardia, Ventri	2022
Ventricular Tachycardia with ICD Shocks: When to Medicate and When to Ablate. Current cardiology reports, 2017, 09-13, Volume: 19, Issue:11 Topics: Amiodarone; Anti-Arrhythmia Agents; Catheter Ablation; Defibrillators, Implantable; Electric Counter	2017
Best Clinical Practice: Emergency Medicine Management of Stable Monomorphic Ventricular Tachycardia. The Journal of emergency medicine, 2017, Volume: 52, Issue:4 Topics: Amiodarone; Anti-Arrhythmia Agents; Electric Countershock; Electrocardiography; Emergency Service, H	2017
Role of drug therapy for sustained ventricular tachyarrhythmias. Cardiology clinics, 2008, Volume: 26, Issue:3 Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Carbazoles; Carvedilol; Digoxin; Heart Conducti	2008
Identification and management of ventricular tachycardia. Journal of the Indian Medical Association, 2003, Volume: 101, Issue:2 Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Catheter Ablation; Defibrillators,	2003
Arrhythmias in the intensive care patient. Current opinion in critical care, 2003, Volume: 9, Issue:5 Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter;	2003
Oral class III antiarrhythmics: what is new? Current opinion in cardiology, 2004, Volume: 19, Issue:1 Topics: Amiodarone; Anti-Arrhythmia Agents; Dronedarone; Humans; Hydantoins; Imidazoles; Imidazolidines; Phe	2004
Adjunctive therapy for recurrent ventricular tachycardia in patients with implantable cardioverter defibrillators. Current cardiology reports, 2007, Volume: 9, Issue:5 Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Combined Modality Therapy; Defibril	2007
Effects of sotalol and d-sotalol on ventricular tachycardia and fibrillation induced by programmed electrical stimulation. European heart journal, 1993, Volume: 14 Suppl H Topics: Adrenergic beta-Antagonists; Cardiac Pacing, Artificial; Clinical Trials as Topic; Heart Conduction	1993
Antiarrhythmic drugs versus implantable defibrillators: the need for a randomized controlled study. American heart journal, 1994, Volume: 127, Issue:4 Pt 2 Topics: Amiodarone; Anti-Arrhythmia Agents; Clinical Trials as Topic; Defibrillators, Implantable; Humans; P	1994
[Tachycardias: considerations in childhood in the 90s]. Anales espanoles de pediatria, 1993, Volume: 39, Issue:6 Topics: Adenosine; Adolescent; Adult; Amiodarone; Atrial Flutter; Child; Child, Preschool; Electrocardiograp	1993
Class III antiarrhythmic drugs. Current opinion in cardiology, 1994, Volume: 9, Issue:1 Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Electrocardiogra	1994
Sotalol. The New England journal of medicine, 1994, Jul-07, Volume: 331, Issue:1 Topics: Action Potentials; Animals; Electrocardiography; Electrophysiology; Humans; Myocardial Contraction;	1994
Sotalol hydrochloride (Betapace): a new antiarrhythmic drug. American journal of critical care : an official publication, American Association of Critical-Care Nurses, 1993, Volume: 2, Issue:5 Topics: Adult; Angina Pectoris; Child; Clinical Protocols; Drug Interactions; Electrophysiology; Female; Hem	1993
Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA, 1993, Dec-01, Volume: 270, Issue:21 Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amiodarone; Bepridil; Cardiovascular Agents; Disopyramid	1993
Empiric use of amiodarone and sotalol. The American journal of cardiology, 1993, Nov-26, Volume: 72, Issue:16 Topics: Amiodarone; Cardiomyopathy, Hypertrophic; Coronary Disease; Death, Sudden, Cardiac; Heart Diseases;	1993
Practical considerations in the use of sotalol for ventricular tachycardia and ventricular fibrillation. The American journal of cardiology, 1993, Aug-12, Volume: 72, Issue:4 Topics: Anti-Arrhythmia Agents; Electrocardiography; Humans; Sotalol; Tachycardia, Ventricular; Ventricular	1993
Sotalol: a novel beta-blocker with class III anti-arrhythmic activity. Journal of clinical pharmacology, 1993, Volume: 33, Issue:6 Topics: Arrhythmias, Cardiac; Heart Ventricles; Hemodynamics; Humans; Myocardial Ischemia; Sotalol; Tachycar	1993
Evolving role of sotalol in the management of ventricular tachyarrhythmias. The American journal of cardiology, 1996, Aug-29, Volume: 78, Issue:4A Topics: Anti-Arrhythmia Agents; Humans; Sotalol; Tachycardia, Ventricular; Ventricular Fibrillation	1996
Beta-blockers for ventricular arrhythmias: have we underestimated their value? Australian and New Zealand journal of medicine, 1996, Volume: 26, Issue:5 Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Clinical Trials as Topic; Humans; R	1996
[Ventricular cardiac arrhythmias. New anti-arrhythmia agents]. Zeitschrift fur Kardiologie, 1996, Volume: 85 Suppl 6 Topics: Amiodarone; Anti-Arrhythmia Agents; Clinical Trials as Topic; Electrocardiography; Heart Conduction	1996
[Pharmacologic therapy of ventricular tachyarrhythmias: value of class III anti-arrhythmia drugs]. Zeitschrift fur Kardiologie, 1996, Volume: 85 Suppl 6 Topics: Amiodarone; Anti-Arrhythmia Agents; Clinical Trials as Topic; Combined Modality Therapy; Death, Sudd	1996
[Drug therapy of ventricular arrhythmias]. Medizinische Klinik (Munich, Germany : 1983), 1997, Apr-15, Volume: 92, Issue:4 Topics: Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Electrocardiography; Hu	1997
Drug-induced cardiac arrhythmias: incidence, prevention and management. Drug safety, 1997, Volume: 17, Issue:4 Topics: Amiodarone; Angiotensin-Converting Enzyme Inhibitors; Anti-Arrhythmia Agents; Anti-Infective Agents;	1997
Drugs versus devices in controlling ventricular tachycardia, ventricular fibrillation, and recurrent cardiac arrest. The American journal of cardiology, 1997, Oct-23, Volume: 80, Issue:8A Topics: Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; Heart Arrest; Humans; Randomized Co	1997
Sotalol: An important new antiarrhythmic. American heart journal, 1999, Volume: 137, Issue:3 Topics: Action Potentials; Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Atrial Fibrillation; Defibri	1999
Drugs for ventricular arrhythmias in the era of the implantable cardioverter defibrillator. European heart journal, 1999, Volume: 20, Issue:5 Topics: Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; Follow-Up Studies; Humans; Sotalol;	1999
Sudden cardiac death: who needs an implantable cardioverter-defibrillator and who needs antiarrhythmic drugs? European heart journal, 1999, Volume: 20, Issue:6 Topics: Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable; Humans; Sec	1999
The role of EP-guided therapy in ventricular arrhythmias: beta-blockers, sotalol, and ICD's. Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2000, Volume: 4 Suppl 1 Topics: Adrenergic beta-Antagonists; Defibrillators, Implantable; Electrophysiology; Female; Humans; Male; P	2000
Is primary antiarrhythmic drug therapy for ventricular arrhythmias obsolete? Current cardiology reports, 1999, Volume: 1, Issue:4 Topics: Amiodarone; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable; Humans; Ran	1999
Efficacy and safety of sotalol in patients with complex ventricular arrhythmias. International journal of cardiology, 1992, Volume: 37, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Cardiac Complexes, Premature; Clinical Trials as Topic; Databases, F	1992

Article	Year
Elimination of Benign Ventricular Premature Beats or Ventricular Tachycardia with Catheter Ablation versus Two Different Optimal Antiarrhythmic Drug Treatment Regimens (Sotalol or Verapamil/Flecainide). Cardiology, 2020, Volume: 145, Issue:12 Topics: Anti-Arrhythmia Agents; Cardiac Complexes, Premature; Catheter Ablation; Flecainide; Humans; Prospec	2020
The effects of nifekalant hydrochloride on the QT dispersion after direct-current defibrillation. Osaka city medical journal, 2008, Volume: 54, Issue:1 Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable;	2008
Combination therapy with mexiletine and sotalol suppresses inherited ventricular arrhythmias in German shepherd dogs better than mexiletine or sotalol monotherapy: a randomized cross-over study. Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology, 2010, Volume: 12, Issue:2 Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cross-Over Studies; Dog Diseases; Dogs; Drug	2010
Efficacy of metoprolol and sotalol in the prevention of recurrences of sustained ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator. Pacing and clinical electrophysiology : PACE, 2002, Volume: 25, Issue:11 Topics: Defibrillators, Implantable; Female; Humans; Male; Metoprolol; Middle Aged; Prospective Studies; Rec	2002
Comparison of efficacy of sotalol and nifekalant for ventricular tachyarrhythmias. Circulation journal : official journal of the Japanese Circulation Society, 2006, Volume: 70, Issue:5 Topics: Adult; Aged; Anti-Arrhythmia Agents; Drug Therapy, Combination; Electric Stimulation; Electrocardiog	2006
Observations on the safety and effectiveness of dofetilide in patients with paroxysmal atrial fibrillation and normal left ventricular function. Journal of cardiovascular pharmacology and therapeutics, 2007, Volume: 12, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flut	2007
Effect of dl-sotalol on mortality and recurrence of ventricular tachyarrhythmias: ischemic compared to nonischemic cardiomyopathy. Pacing and clinical electrophysiology : PACE, 2007, Volume: 30, Issue:9 Topics: Aged; Anti-Arrhythmia Agents; Cardiomyopathies; Comorbidity; Female; Humans; Incidence; Japan; Male;	2007
Results of Holter ECG guided therapy for ventricular arrhythmias: the ESVEM trial. Pacing and clinical electrophysiology : PACE, 1994, Volume: 17, Issue:3 Pt 2 Topics: Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Death, Sudden, Cardiac; Electrocardiography, Amb	1994
Effects of amiodarone, sematilide, and sotalol on QT dispersion. The American journal of cardiology, 1994, Nov-01, Volume: 74, Issue:9 Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiac Complexes, Premature; Electrocardiography; Follow-	1994
Randomized crossover comparison of the electrophysiologic and antiarrhythmic efficacy of oral cibenzoline and sotalol for sustained ventricular tachycardia. Journal of cardiovascular pharmacology, 1993, Volume: 21, Issue:1 Topics: Administration, Oral; Adult; Anti-Arrhythmia Agents; Electrocardiography; Electrophysiology; Female;	1993
Randomized cross-over evaluation of two adaptive pacing algorithms for the termination of ventricular tachycardia. Pacing and clinical electrophysiology : PACE, 1993, Volume: 16, Issue:8 Topics: Adult; Aged; Aged, 80 and over; Algorithms; Bundle-Branch Block; Cardiac Pacing, Artificial; Defibri	1993
Insights into the Electrophysiology Study Versus Electrocardiographic Monitoring Trial: its programmed stimulation protocol may introduce bias when assessing long-term antiarrhythmic drug therapy. Journal of the American College of Cardiology, 1995, Volume: 25, Issue:7 Topics: Anti-Arrhythmia Agents; Bias; Cardiac Pacing, Artificial; Drug Combinations; Electrocardiography, Am	1995
Multicenter trial of sotalol compared with procainamide in the suppression of inducible ventricular tachycardia: a double-blind, randomized parallel evaluation. Sotalol Multicenter Study Group. American heart journal, 1995, Volume: 129, Issue:1 Topics: Administration, Oral; Adolescent; Adult; Aged; Cardiac Pacing, Artificial; Double-Blind Method; Elec	1995
[Efficacy of sotalol in idiopathic ventricular arrhythmia originating in the right ventricular outflow tract]. Arquivos brasileiros de cardiologia, 1994, Volume: 63, Issue:1 Topics: Adult; Circadian Rhythm; Double-Blind Method; Female; Humans; Male; Middle Aged; Sotalol; Tachycardi	1994
Antiarrhythmics Versus Implantable Defibrillators (AVID)--rationale, design, and methods. The American journal of cardiology, 1995, Mar-01, Volume: 75, Issue:7 Topics: Amiodarone; Cross-Over Studies; Defibrillators, Implantable; Humans; Prospective Studies; Quality of	1995
Double-blind trial of lignocaine versus sotalol for acute termination of spontaneous sustained ventricular tachycardia. Lancet (London, England), 1994, Jul-02, Volume: 344, Issue:8914 Topics: Adult; Aged; Aged, 80 and over; Double-Blind Method; Female; Humans; Lidocaine; Male; Middle Aged; S	1994
Electrophysiologic effects of sotalol and amiodarone in patients with sustained monomorphic ventricular tachycardia. The American journal of cardiology, 1994, Dec-01, Volume: 74, Issue:11 Topics: Aged; Amiodarone; Analysis of Variance; Chi-Square Distribution; Electrophysiology; Female; Humans;	1994
Comparative effects of the combination of digoxin and dl-sotalol therapy versus digoxin monotherapy for control of ventricular response in chronic atrial fibrillation. dl-Sotalol Atrial Fibrillation Study Group. American heart journal, 1994, Volume: 127, Issue:3 Topics: Atrial Fibrillation; Chronic Disease; Digoxin; Double-Blind Method; Drug Therapy, Combination; Elect	1994
Antiarrhythmic drugs versus implantable defibrillators: the need for a randomized controlled study. American heart journal, 1994, Volume: 127, Issue:4 Pt 2 Topics: Amiodarone; Anti-Arrhythmia Agents; Clinical Trials as Topic; Defibrillators, Implantable; Humans; P	1994
Comparative efficacy of sotalol and class I antiarrhythmic agents in patients with ventricular tachycardia or fibrillation: results of the Electrophysiology Study Versus Electrocardiographic Monitoring (ESVEM) Trial. European heart journal, 1993, Volume: 14 Suppl H Topics: Actuarial Analysis; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Electrocardiography, Ambulat	1993
Acute and chronic antiarrhythmic efficacy of d-sotalol in patients with sustained ventricular tachyarrhythmias. European heart journal, 1993, Volume: 14 Suppl H Topics: Cardiac Pacing, Artificial; Female; Follow-Up Studies; Humans; Male; Middle Aged; Sotalol; Stereoiso	1993
Safety and efficacy of oral sotalol for sustained ventricular tachyarrhythmias refractory to other antiarrhythmic agents. The American journal of cardiology, 1993, Aug-12, Volume: 72, Issue:4 Topics: Administration, Oral; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Electrocardiography, Ambul	1993
Sotalol and type IA drugs in combination prevent recurrence of sustained ventricular tachycardia. Journal of the American College of Cardiology, 1993, Volume: 22, Issue:1 Topics: Aged; Cardiac Pacing, Artificial; Drug Therapy, Combination; Electrocardiography; Female; Humans; Ma	1993
Metoprolol versus sotalol in the treatment of sustained ventricular tachycardia. Journal of cardiovascular pharmacology, 1995, Volume: 26, Issue:4 Topics: Administration, Oral; Adrenergic beta-Antagonists; Adult; Aged; Anti-Arrhythmia Agents; Arrhythmias,	1995
Reverse use dependence of human ventricular repolarization by chronic oral sotalol in monophasic action potential recordings. The American journal of cardiology, 1996, May-01, Volume: 77, Issue:11 Topics: Action Potentials; Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Dose-Response Relationship, Drug	1996
Continuation of antiarrhythmic drugs, or arrhythmia surgery after multiple drug failures. A randomized trial in the treatment of postinfarction ventricular tachycardia. European heart journal, 1996, Volume: 17, Issue:4 Topics: Adult; Aged; Anti-Arrhythmia Agents; Female; Flecainide; Humans; Male; Middle Aged; Propafenone; Sot	1996
[Brazilian multicenter study of sotalol effectiveness in ventricular arrhythmias]. Arquivos brasileiros de cardiologia, 1996, Volume: 66, Issue:3 Topics: Administration, Oral; Adult; Aged; Analysis of Variance; Anti-Arrhythmia Agents; Arrhythmias, Cardia	1996
d-Sotalol decreases defibrillation energy requirements in humans: a novel indication for drug therapy. Journal of cardiovascular electrophysiology, 1996, Volume: 7, Issue:10 Topics: Adrenergic beta-Antagonists; Defibrillators, Implantable; Electrocardiography; Female; Heart Rate; H	1996
Sotalol for ventricular tachyarrhythmias: beta-blocking and class III contributions, and relative efficacy versus class I drugs after prior drug failure. ESVEM Investigators. Electrophysiologic Study Versus Electrocardiographic Monitoring. The American journal of cardiology, 1997, Apr-15, Volume: 79, Issue:8 Topics: Adrenergic beta-Antagonists; Aged; Anti-Arrhythmia Agents; Drug Interactions; Drug Therapy, Combinat	1997
Risk stratification and clinical outcome of minimally symptomatic and asymptomatic patients with nonsustained ventricular tachycardia and coronary disease: a prospective single-center study. The American journal of cardiology, 1997, Sep-11, Volume: 80, Issue:5B Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Confounding Factors, Epidemiologic; Coronary Disease; Deat	1997
A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The New England journal of medicine, 1997, 11-27, Volume: 337, Issue:22 Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; Female; Humans; Male; Middle	1997
A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The New England journal of medicine, 1997, 11-27, Volume: 337, Issue:22 Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; Female; Humans; Male; Middle	1997
A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The New England journal of medicine, 1997, 11-27, Volume: 337, Issue:22 Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; Female; Humans; Male; Middle	1997
A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The New England journal of medicine, 1997, 11-27, Volume: 337, Issue:22 Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; Female; Humans; Male; Middle	1997
A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The New England journal of medicine, 1997, 11-27, Volume: 337, Issue:22 Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; Female; Humans; Male; Middle	1997
A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The New England journal of medicine, 1997, 11-27, Volume: 337, Issue:22 Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; Female; Humans; Male; Middle	1997
A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The New England journal of medicine, 1997, 11-27, Volume: 337, Issue:22 Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; Female; Humans; Male; Middle	1997
A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The New England journal of medicine, 1997, 11-27, Volume: 337, Issue:22 Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; Female; Humans; Male; Middle	1997
A comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. The New England journal of medicine, 1997, 11-27, Volume: 337, Issue:22 Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; Female; Humans; Male; Middle	1997
[Evaluation of antiarrhythmic efficacy of sotalol in various doses in patients with ventricular tachyarrhythmias]. Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 1997, Volume: 2, Issue:8 Topics: Adult; Aged; Anti-Arrhythmia Agents; Dose-Response Relationship, Drug; Drug Administration Schedule;	1997
Comparison of metoprolol and sotalol in preventing ventricular tachyarrhythmias after the implantation of a cardioverter/defibrillator. The American journal of cardiology, 1998, Sep-15, Volume: 82, Issue:6 Topics: Adolescent; Adult; Anti-Arrhythmia Agents; Defibrillators, Implantable; Electrocardiography; Female;	1998
Suppression of sustained ventricular tachyarrhythmias: a comparison of d,l-sotalol with no antiarrhythmic drug treatment. Journal of the American College of Cardiology, 1999, Volume: 33, Issue:1 Topics: Administration, Oral; Aged; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Defibrillators, Impl	1999
Efficacy and efficacy testing of sotalol. Journal of the American College of Cardiology, 1999, Volume: 33, Issue:1 Topics: Adult; Aged; Anti-Arrhythmia Agents; Defibrillators, Implantable; Female; Humans; Male; Middle Aged;	1999
Comparison of sotalol with amiodarone for long-term treatment of spontaneous sustained ventricular tachyarrhythmia based on coronary artery disease. European heart journal, 1999, Volume: 20, Issue:5 Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Coronary Disease; Cross-Over Studies; Electrocardiography;	1999
Predicting the effect of D,L-sotalol on ventricular tachycardia inducibility from the RR variability response. Heart (British Cardiac Society), 1999, Volume: 82, Issue:3 Topics: Adrenergic beta-Antagonists; Adult; Aged; Anti-Arrhythmia Agents; Electric Stimulation; Electrocardi	1999
Determinants of outcome in patients with sustained ventricular tachyarrhythmias: the antiarrhythmics versus implantable defibrillators (AVID) study registry. American heart journal, 2000, Volume: 139, Issue:5 Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Defibrillators, Implantable; Female; Humans; Male; Middle	2000
Prophylaxis of supraventricular and ventricular arrhythmias after coronary artery bypass grafting with low-dose sotalol. The Annals of thoracic surgery, 2000, Volume: 70, Issue:1 Topics: Administration, Oral; Anti-Arrhythmia Agents; Coronary Artery Bypass; Female; Humans; Male; Middle A	2000
Repolarization changes in a double-blind crossover study of dofetilide versus sotalol in the treatment of ventricular tachycardia. Pacing and clinical electrophysiology : PACE, 2000, Volume: 23, Issue:11 Pt 2 Topics: Anti-Arrhythmia Agents; Cross-Over Studies; Double-Blind Method; Electrocardiography; Female; Humans	2000
Single-dose pharmacokinetics of sotalol in a pediatric population with supraventricular and/or ventricular tachyarrhythmia. Journal of clinical pharmacology, 2001, Volume: 41, Issue:1 Topics: Adrenergic beta-Antagonists; Aging; Anti-Arrhythmia Agents; Child; Child, Preschool; Drug Administra	2001
Pharmacokinetics and pharmacodynamics of sotalol in a pediatric population with supraventricular and ventricular tachyarrhythmia. Clinical pharmacology and therapeutics, 2001, Volume: 69, Issue:3 Topics: Anti-Arrhythmia Agents; Area Under Curve; Child; Child, Preschool; Dose-Response Relationship, Drug;	2001
Effect of metoprolol and d,l-sotalol on microvolt-level T-wave alternans. Results of a prospective, double-blind, randomized study. Journal of the American College of Cardiology, 2001, Volume: 38, Issue:7 Topics: Adrenergic beta-Antagonists; Aged; Anti-Arrhythmia Agents; Cause of Death; Coronary Disease; Death,	2001
A multicentre, double-blind randomized crossover comparative study on the efficacy and safety of dofetilide vs sotalol in patients with inducible sustained ventricular tachycardia and ischaemic heart disease. European heart journal, 2001, Volume: 22, Issue:23 Topics: Adult; Aged; Anti-Arrhythmia Agents; Cross-Over Studies; Double-Blind Method; Female; Humans; Male;	2001
Population pharmacokinetics and pharmacodynamics of sotalol in pediatric patients with supraventricular or ventricular tachyarrhythmia. Journal of pharmacokinetics and pharmacodynamics, 2001, Volume: 28, Issue:6 Topics: Anti-Arrhythmia Agents; Child; Child, Preschool; Dose-Response Relationship, Drug; Female; Humans; I	2001

Article	Year
Safety and efficacy of flecainide associated with beta-blockers in arrhythmogenic right ventricular cardiomyopathy. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2022, 02-02, Volume: 24, Issue:2 Topics: Arrhythmogenic Right Ventricular Dysplasia; Atrial Fibrillation; Defibrillators, Implantable; Flecai	2022
The Feasibility and Safety of Flecainide Use Among Patients With Varying Degrees of Coronary Disease. JACC. Clinical electrophysiology, 2023, Volume: 9, Issue:7 Pt 2 Topics: Coronary Artery Disease; Feasibility Studies; Flecainide; Humans; Retrospective Studies; Sotalol; Ta	2023
Adverse event rate during inpatient sotalol initiation for the management of supraventricular and ventricular tachycardia in the pediatric and young adult population. Heart rhythm, 2020, Volume: 17, Issue:6 Topics: Anti-Arrhythmia Agents; Atrial Fibrillation; Child, Preschool; Electrocardiography, Ambulatory; Fema	2020
Exercise-induced ventricular tachycardia in a case with hypertrophic cardiomyopathy taking cibenzoline. Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc, 2021, Volume: 26, Issue:1 Topics: Adolescent; Anti-Arrhythmia Agents; Cardiomyopathy, Hypertrophic; Cardiopulmonary Resuscitation; Exe	2021
The Efficacy of Anti-Arrhythmic Drugs in Children With Idiopathic Frequent Symptomatic or Asymptomatic Premature Ventricular Complexes With or Without Asymptomatic Ventricular Tachycardia: a Retrospective Multi-Center Study. Pediatric cardiology, 2021, Volume: 42, Issue:4 Topics: Adolescent; Adrenergic beta-Antagonists; Anti-Arrhythmia Agents; Child; Child, Preschool; Female; Fl	2021
Use of Antiarrhythmic Medications in Medicare Part D Patients With an Implantable Cardioverter-Defibrillator and Ventricular Tachycardia. The American journal of cardiology, 2017, 05-01, Volume: 119, Issue:9 Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Databases,	2017
Early experience with intravenous sotalol in children with and without congenital heart disease. Heart rhythm, 2018, Volume: 15, Issue:12 Topics: Administration, Intravenous; Adolescent; Anti-Arrhythmia Agents; Child; Child, Preschool; Dose-Respo	2018
Ventricular arrhythmia and death among atrial fibrillation patients using anti-arrhythmic drugs. American heart journal, 2018, Volume: 205 Topics: Aged; Anti-Arrhythmia Agents; Atrial Fibrillation; Cause of Death; Dronedarone; Female; Flecainide;	2018
Ivabradine Aggravates the Proarrhythmic Risk in Experimental Models of Long QT Syndrome. Cardiovascular toxicology, 2019, Volume: 19, Issue:2 Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Heart Conduction System; Heart Rate; Isolated He	2019
ECG of the month. Ventricular arrhythmia in a dog. Journal of the American Veterinary Medical Association, 2013, Aug-01, Volume: 243, Issue:3 Topics: Animals; Anti-Arrhythmia Agents; Dog Diseases; Dogs; Electrocardiography; Fatal Outcome; Female; Mex	2013
Combination drug therapy for patients with intractable ventricular tachycardia associated with right ventricular cardiomyopathy. Pacing and clinical electrophysiology : PACE, 2014, Volume: 37, Issue:1 Topics: Adult; Aged; Anti-Arrhythmia Agents; Arrhythmogenic Right Ventricular Dysplasia; Chronic Disease; Dr	2014
Drug-induced post-repolarization refractoriness as an antiarrhythmic principle and its underlying mechanism. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2014, Volume: 16 Suppl 4 Topics: Action Potentials; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Cardiac Pacing, Arti	2014
Implantable cardioverter-defibrillator therapy in Brugada syndrome: a 20-year single-center experience. Journal of the American College of Cardiology, 2015, Mar-10, Volume: 65, Issue:9 Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Anti-Arrhythmia Agents; Belgium; Brugada Syndr	2015
Non-sustained ventricular tachycardia in a pregnant woman with repaired Tetralogy of Fallot: A challenging case. International journal of cardiology, 2016, Jan-15, Volume: 203 Topics: Adult; Anti-Arrhythmia Agents; Death, Sudden, Cardiac; Defibrillators, Implantable; Female; Humans;	2016
Efficacy of Intravenous Sotalol for Treatment of Incessant Tachyarrhythmias in Children. The American journal of cardiology, 2017, 05-01, Volume: 119, Issue:9 Topics: Adolescent; Anti-Arrhythmia Agents; Atrial Fibrillation; Atrial Flutter; Child; Child, Preschool; Dr	2017
d,l-Sotalol at therapeutic concentrations facilitates the occurrence of long-lasting non-stationary reentry during ventricular fibrillation in isolated rabbit hearts. Circulation journal : official journal of the Japanese Circulation Society, 2009, Volume: 73, Issue:1 Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Disease Models, Animal; Dose-Response Relationsh	2009
Implantable cardioverter defibrillator therapy for patients with chronic Chagas' disease: a randomized trial may not be necessary in high-risk patients. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2009, Volume: 11, Issue:4 Topics: Amiodarone; Animals; Anti-Arrhythmia Agents; Chagas Cardiomyopathy; Chagas Disease; Chronic Disease;	2009
Post induction arrhythmia in a renal patient: an unexpected risk factor. Anaesthesia, 2009, Volume: 64, Issue:4 Topics: Adrenergic beta-Antagonists; Adult; Anti-Arrhythmia Agents; Electrocardiography; Female; Humans; Int	2009
Efficacy of antiarrhythmic drugs in arrhythmogenic right ventricular cardiomyopathy: a report from the North American ARVC Registry. Journal of the American College of Cardiology, 2009, Aug-11, Volume: 54, Issue:7 Topics: Adrenergic beta-Antagonists; Adult; Amiodarone; Anti-Arrhythmia Agents; Arrhythmogenic Right Ventric	2009
Empiric antiarrhythmic drug therapy in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia: pragmatism or anachronism? Journal of the American College of Cardiology, 2009, Aug-11, Volume: 54, Issue:7 Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Arrhythmogenic Right Ventricular Dy	2009
[Life-threatening ventricular arrhythmia during simultaneous administration of propafenone and sotatol]. Kardiologia polska, 2009, Volume: 67, Issue:8 Topics: Anti-Arrhythmia Agents; Drug Therapy, Combination; Electrocardiography; Humans; Male; Middle Aged; P	2009
Termination of recurrent ventricular tachycardia by continuous positive airway pressure ventilation. Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc, 2009, Volume: 14, Issue:4 Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Carbazoles; Cardiomyopathy, H	2009
Mortality and safety of catheter ablation for antiarrhythmic drug-refractory ventricular tachycardia in elderly patients with coronary artery disease. Heart rhythm, 2010, Volume: 7, Issue:6 Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Amiodarone; Anti-Arrhythmia Agents; Body Surface Pot	2010
ECG of the month. Arrhythmogenic right ventricular cardiomyopathy in a Boxer. Journal of the American Veterinary Medical Association, 2010, May-01, Volume: 236, Issue:9 Topics: Animals; Anti-Arrhythmia Agents; Antihypertensive Agents; Benzazepines; Cardiomyopathies; Cardiotoni	2010
A comparison of long-standing implantable cardioverter-defibrillator patients with and without appropriate therapy for ventricular arrhythmias: impact of a widening QRS. Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology, 2011, Volume: 13, Issue:1 Topics: Adrenergic beta-Antagonists; Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Combined Modality Ther	2011
First direct comparison of the late sodium current blocker ranolazine to established antiarrhythmic agents in an ischemia/reperfusion model. Journal of cardiovascular pharmacology and therapeutics, 2011, Volume: 16, Issue:2 Topics: Acetanilides; Animals; Anti-Arrhythmia Agents; Enzyme Inhibitors; Female; Infusions, Intravenous; In	2011
Guidelines for the diagnosis and management of arrhythmogenic right ventricular cardiomyopathy. Heart, lung & circulation, 2011, Volume: 20, Issue:12 Topics: Amiodarone; Anti-Arrhythmia Agents; Arrhythmogenic Right Ventricular Dysplasia; Defibrillators, Impl	2011
Ranolazine reduces ventricular tachycardia burden and ICD shocks in patients with drug-refractory ICD shocks. Pacing and clinical electrophysiology : PACE, 2011, Volume: 34, Issue:12 Topics: Acetanilides; Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathy, Dilated; Cohort Studies; Def	2011
Cardiac sarcoidosis masquerading as arrhythmogenic right ventricular cardiomyopathy. Heart, lung & circulation, 2012, Volume: 21, Issue:1 Topics: Adrenal Cortex Hormones; Adult; Anti-Arrhythmia Agents; Arrhythmogenic Right Ventricular Dysplasia;	2012
Acute inhibition of the Na(+)/Ca(2+) exchanger reduces proarrhythmia in an experimental model of chronic heart failure. Heart rhythm, 2012, Volume: 9, Issue:4 Topics: Action Potentials; Amiodarone; Animals; Anti-Arrhythmia Agents; Disease Models, Animal; Heart; Heart	2012
Implantable cardiac defibrillators. The New England journal of medicine, 2002, Aug-01, Volume: 347, Issue:5 Topics: Amiodarone; Anti-Arrhythmia Agents; Combined Modality Therapy; Defibrillators, Implantable; Humans;	2002
Prolonged action potential durations, increased dispersion of repolarization, and polymorphic ventricular tachycardia in a mouse model of proarrhythmia. Basic research in cardiology, 2003, Volume: 98, Issue:1 Topics: Action Potentials; Animals; Arrhythmias, Cardiac; Disease Models, Animal; Electrocardiography; Elect	2003
Clinical usefulness of electrophysiologic testing in patients with ventricular tachycardia and chronic chagasic cardiomyopathy treated with amiodarone or sotalol. Journal of cardiovascular electrophysiology, 2003, Volume: 14, Issue:6 Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Brazil; Chagas Cardiomyopathy; Death, Sudden, Cardiac; Dr	2003
Do we need a randomized trial of defibrillator therapy in every subset of patients with increased risk of sudden death? Journal of cardiovascular electrophysiology, 2003, Volume: 14, Issue:6 Topics: Amiodarone; Anti-Arrhythmia Agents; Chagas Cardiomyopathy; Death, Sudden, Cardiac; Defibrillators, I	2003
Beta receptor blockade potentiates the antiarrhythmic actions of d-sotalol on reentrant ventricular tachycardia in a canine model of myocardial infarction. Journal of cardiovascular electrophysiology, 2003, Volume: 14, Issue:11 Topics: Adrenergic beta-Antagonists; Animals; Anti-Arrhythmia Agents; Dogs; Drug Synergism; Electrocardiogra	2003
Sotalol-induced coronary spasm in a patient with dilated cardiomyopathy associated with sustained ventricular tachycardia. Internal medicine (Tokyo, Japan), 2004, Volume: 43, Issue:11 Topics: Anti-Arrhythmia Agents; Calcium Channel Blockers; Cardiomyopathy, Dilated; Coronary Angiography; Cor	2004
Advantages and pitfalls of combining device-based and pharmacologic therapies for the treatment of ventricular arrhythmias: observations from a tertiary referral center. Pacing and clinical electrophysiology : PACE, 2004, Volume: 27, Issue:12 Topics: Amiodarone; Anti-Arrhythmia Agents; Bradycardia; Combined Modality Therapy; Defibrillators, Implanta	2004
Electrophysiologic study-guided therapy with sotalol for life-threatening ventricular tachyarrhythmias. Pacing and clinical electrophysiology : PACE, 2005, Volume: 28, Issue:4 Topics: Aged; Analysis of Variance; Anti-Arrhythmia Agents; Chi-Square Distribution; Defibrillators, Implant	2005
Proarrhythmias and antiarrhythmias: two sides of the same coin. Heart rhythm, 2005, Volume: 2, Issue:9 Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac Pacing	2005
Potential proarrhythmic effect of biventricular pacing: fact or myth? Heart rhythm, 2005, Volume: 2, Issue:9 Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Atrial Fibrillation; Cardiac	2005
Tachycardia-induced elevations in cardiac troponin in the absence of coronary artery disease. Hawaii medical journal, 2006, Volume: 65, Issue:3 Topics: Administration, Oral; Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Catheter Abla	2006
Electrophysiologic actions of d,l-sotalol and GLG-V-13 in ischemically injured canine epicardium. Journal of cardiovascular pharmacology, 2007, Volume: 50, Issue:3 Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Bridged Bicyclo Compounds, Heterocyclic; Coronar	2007
Interaction of acute ventricular dilatation and d-sotalol during sustained reentrant ventricular tachycardia around a fixed obstacle. Circulation, 1994, Volume: 89, Issue:1 Topics: Animals; Cardiac Complexes, Premature; Cardiac Pacing, Artificial; Female; Heart Block; Heart Conduc	1994
Response to sotalol predicts the response to amiodarone during serial drug testing in patients with sustained ventricular tachycardia and coronary artery disease. The American journal of cardiology, 1994, Feb-15, Volume: 73, Issue:5 Topics: Amiodarone; Cardiac Complexes, Premature; Cardiac Pacing, Artificial; Cohort Studies; Coronary Disea	1994
AVID necessity. Pacing and clinical electrophysiology : PACE, 1994, Volume: 17, Issue:2 Topics: Amiodarone; Arrhythmias, Cardiac; Bias; Clinical Trials as Topic; Defibrillators, Implantable; Ethic	1994
[Results of oral sotalol therapy in children with supraventricular and ventricular arrhythmias]. Zeitschrift fur Kardiologie, 1994, Volume: 83, Issue:12 Topics: Administration, Oral; Adolescent; Adult; Atrial Flutter; Atrioventricular Node; Cardiac Complexes, P	1994
Sotalol for refractory arrhythmias in pediatric and young adult patients: initial efficacy and long-term outcome. American heart journal, 1995, Volume: 130, Issue:4 Topics: Adolescent; Adult; Anti-Arrhythmia Agents; Child; Child, Preschool; Female; Heart Conduction System;	1995
[Comments on the contribution by Prof. Dr. S. H. Hohnloser. Sotalol]. Der Internist, 1995, Volume: 36, Issue:7 Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Metabolic Clearance Rate; So	1995
Antiarrhythmic effect of a sotalol-mexiletine combination on induced ventricular tachycardia in dogs. Journal of cardiovascular pharmacology, 1993, Volume: 21, Issue:2 Topics: Animals; Coronary Vessels; Dogs; Drug Combinations; Electric Stimulation; Electrocardiography; Elect	1993
Relation of diurnal variation of ventricular repolarization to ventricular ectopic activity and modification by sotalol. The American journal of cardiology, 1993, Feb-15, Volume: 71, Issue:5 Topics: Cardiac Complexes, Premature; Circadian Rhythm; Electrocardiography, Ambulatory; Female; Heart Condu	1993
Cellular mechanism underlying the efficacy of the sotalol-quinidine combination. Journal of cardiovascular pharmacology, 1993, Volume: 21, Issue:4 Topics: Action Potentials; Animals; Drug Combinations; Electric Stimulation; Guinea Pigs; Muscle, Smooth, Va	1993
Effects of sotalol on the function of implanted pacemakers. American heart journal, 1995, Volume: 129, Issue:5 Topics: Aged; Aged, 80 and over; Combined Modality Therapy; Dose-Response Relationship, Drug; Drug Evaluatio	1995
Sotalol and the management of ventricular arrhythmias: implications of ESVEM. Pacing and clinical electrophysiology : PACE, 1995, Volume: 18, Issue:3 Pt 1 Topics: Electrocardiography, Ambulatory; Humans; Sotalol; Tachycardia, Ventricular	1995
Clinical implications of pleomorphic ventricular tachycardias on oral sotalol therapy. European heart journal, 1995, Volume: 16, Issue:3 Topics: Administration, Oral; Adult; Aged; Cardiac Pacing, Artificial; Coronary Disease; Electrocardiography	1995
Treatment of ventricular tachycardia. Lancet (London, England), 1994, Nov-05, Volume: 344, Issue:8932 Topics: Humans; Lidocaine; Procainamide; Sotalol; Tachycardia, Ventricular	1994
Electrophysiological mechanisms of action of the levorotatory isomer of sotalol in a canine infarct model of inducible ventricular tachycardia: comparison with the beta-1 receptor antagonist bisoprolol. Journal of molecular and cellular cardiology, 1994, Volume: 26, Issue:7 Topics: Animals; Bisoprolol; Disease Models, Animal; Dogs; Electric Stimulation; Electrocardiography; Female	1994
Undersensing during ventricular tachyarrhythmias in a third-generation implantable cardioverter defibrillator: diagnosis using stored electrograms and correction with programming. Pacing and clinical electrophysiology : PACE, 1994, Volume: 17, Issue:9 Topics: Aged; Atrial Fibrillation; Defibrillators, Implantable; Electrocardiography; Electrophysiology; Equi	1994
[Effect of sotalol on heart rate variability in patients with symptomatic, complex ventricular arrhythmias]. Zeitschrift fur Kardiologie, 1994, Volume: 83, Issue:4 Topics: Adult; Aged; Autonomic Nervous System; Dose-Response Relationship, Drug; Drug Administration Schedul	1994
Effects of heptanol, class Ic, and class III drugs on reentrant ventricular tachycardia. Importance of the excitable gap for the inducibility of double-wave reentry. Circulation, 1994, Volume: 90, Issue:2 Topics: Alcohols; Animals; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Electrocardiography; Estrenes	1994
Sotalol in Life-Threatening Ventricular Arrhythmias: A Unique Class III Antiarrhythmic. Symposium proceedings. Phoenix, Arizona, September 19-22, 1991. The American journal of cardiology, 1993, Aug-12, Volume: 72, Issue:4 Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Humans; Sotalol; Tachycardia, Ventricular	1993
Efficacy of sotalol guided by programmed electrical stimulation for sustained ventricular arrhythmias secondary to coronary artery disease. The American journal of cardiology, 1994, Apr-01, Volume: 73, Issue:9 Topics: Aged; Cardiac Pacing, Artificial; Coronary Disease; Electrophysiology; Female; Humans; Male; Middle	1994
[Diagnosis of long QT syndrome with the help of atropine provoked ventricular tachycardia]. Ugeskrift for laeger, 1994, Jan-31, Volume: 156, Issue:5 Topics: Atropine; Electrocardiography; Female; Humans; Injections, Intravenous; Long QT Syndrome; Middle Age	1994
Beat-to-beat variability of ventricular late potentials in the unaveraged high resolution electrocardiogram--effects of antiarrhythmic drugs. European heart journal, 1993, Volume: 14 Suppl E Topics: Action Potentials; Aged; Anti-Arrhythmia Agents; Cardiomyopathy, Dilated; Coronary Disease; Electroc	1993
Effect of oral sotalol on systemic hemodynamics and programmed electrical stimulation in patients with ventricular arrhythmias and structural heart disease. The American journal of cardiology, 1993, Aug-12, Volume: 72, Issue:4 Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Arrhythmias, Cardiac; Cardiac Pacing, Artifici	1993
Sotalol for cardiac arrhythmias. The Medical letter on drugs and therapeutics, 1993, Apr-02, Volume: 35, Issue:893 Topics: Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Clinical Trials as Topic; Humans; Sotalol; Tachycardia	1993
Sotalol marketed for life-threatening arrhythmias. Clinical pharmacy, 1993, Volume: 12, Issue:3 Topics: Administration, Oral; Arrhythmias, Cardiac; Drug Approval; Humans; Sotalol; Tachycardia, Ventricular	1993
Sotalol. New weapon against ventricular arrhythmias. Nursing, 1995, Volume: 25, Issue:12 Topics: Anti-Arrhythmia Agents; Drug Monitoring; Humans; Male; Middle Aged; Patient Education as Topic; Sota	1995
A simulation study used to design the sequential monitoring plan for a clinical trial. Statistics in medicine, 1995, Oct-30, Volume: 14, Issue:20 Topics: Amiodarone; Anti-Arrhythmia Agents; Computer Simulation; Decision Making; Defibrillators, Implantabl	1995
Effects of a new amiodarone-like agent, SR 33589, in comparison to amiodarone, D,L-sotalol, and lignocaine, on ischemia-induced ventricular arrhythmias in anesthetized pigs. Journal of cardiovascular pharmacology, 1995, Volume: 26, Issue:4 Topics: Amiodarone; Analysis of Variance; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Benzofurans	1995
Comparison of d,l-sotalol and implantable defibrillators for treatment of sustained ventricular tachycardia or fibrillation in patients with coronary artery disease. Circulation, 1996, Jul-15, Volume: 94, Issue:2 Topics: Administration, Oral; Case-Control Studies; Combined Modality Therapy; Coronary Disease; Defibrillat	1996
Discontinuation of Sotazide. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 1996, Volume: 86, Issue:4 Topics: Anti-Arrhythmia Agents; Antihypertensive Agents; Arrhythmias, Cardiac; Contraindications; Drug Combi	1996
Suppression of ventricular tachycardia by sotalol in myotonic dystrophy. American heart journal, 1996, Volume: 132, Issue:2 Pt 1 Topics: Adrenergic beta-Antagonists; Adult; Anti-Arrhythmia Agents; Electrocardiography; Humans; Male; Myoto	1996
Sotalol proarrhythmia: a report of five cases and an audit of the use of a sotalol in a teaching hospital. Australian and New Zealand journal of medicine, 1996, Volume: 26, Issue:2 Topics: Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Atrial Fibrillation; Female; Hospitals, Teac	1996
Effect of sotalol on RR interval variability during induced ventricular tachycardia. The American journal of cardiology, 1996, Aug-01, Volume: 78, Issue:3 Topics: Adult; Aged; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Drug Evaluation; Electrocardiograph	1996
From first class to third class: recent upheaval in antiarrhythmic therapy--lessons from clinical trials. The American journal of cardiology, 1996, Aug-29, Volume: 78, Issue:4A Topics: Adrenergic beta-Antagonists; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Heart Conduct	1996
Differential effect of selected antiarrhythmic drugs on coronary artery ligation-induced ventricular arrhythmias on the right or left sides. Methods and findings in experimental and clinical pharmacology, 1995, Volume: 17, Issue:5 Topics: Animals; Anti-Arrhythmia Agents; Coronary Disease; Disease Models, Animal; Dogs; Female; Ligation; M	1995
Frequency-dependent electrophysiologic effects of d,l-sotalol and quinidine and modulation by beta-adrenergic stimulation. Journal of cardiovascular electrophysiology, 1996, Volume: 7, Issue:2 Topics: Action Potentials; Administration, Oral; Adrenergic beta-Agonists; Analysis of Variance; Anti-Arrhyt	1996
Long-term efficacy of d/l sotalol in patients with sustained ventricular tachycardia refractory to class I antiarrhythmic drugs. European heart journal, 1995, Volume: 16, Issue:11 Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Drug Resistan	1995
Long-term results of electrophysiologically guided sotalol therapy for life-threatening ventricular arrhythmias. American heart journal, 1996, Volume: 132, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Female; Humans; Male;	1996
Electrophysiologic mechanisms of antiarrhythmic efficacy of a sotalol and class Ia drug combination: elimination of reverse use dependence. Journal of the American College of Cardiology, 1997, Volume: 29, Issue:1 Topics: Action Potentials; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Drug Therapy, Combination; El	1997
Efficacy and proarrhythmia with the use of d,l-sotalol for sustained ventricular tachyarrhythmias. Journal of cardiovascular pharmacology, 1997, Volume: 29, Issue:3 Topics: Adult; Anti-Arrhythmia Agents; Electrocardiography; Female; Follow-Up Studies; Humans; Male; Middle	1997
Usefulness of isoproterenol in the induction of clinical sustained ventricular tachycardia during electrophysiological study. Acta cardiologica, 1997, Volume: 52, Issue:1 Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Aged; Atenolol; Cardiac Pacing, Artificial; E	1997
Clinical predictors of defibrillation energy requirements. The American journal of cardiology, 1997, Jan-15, Volume: 79, Issue:2 Topics: Age Factors; Amiodarone; Anti-Arrhythmia Agents; Cardiac Surgical Procedures; Coronary Disease; Defi	1997
Efficacy and safety of d,l-sotalol in patients with ventricular tachycardia and in survivors of cardiac arrest. Journal of the American College of Cardiology, 1997, Volume: 30, Issue:2 Topics: Administration, Oral; Anti-Arrhythmia Agents; Electric Stimulation; Female; Follow-Up Studies; Heart	1997
Reproducible induction of "atypical" torsades de pointes by programmed electrical stimulation: a novel form of sotalol-induced proarrhythmia? Journal of cardiovascular electrophysiology, 1997, Volume: 8, Issue:9 Topics: Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Electric Stimulation; Electrocardiography; Human	1997
Why the antiarrhythmics versus implantable defibrillator (AVID) trial sets the wrong precedent. The American journal of cardiology, 1997, Sep-15, Volume: 80, Issue:6 Topics: Amiodarone; Anti-Arrhythmia Agents; Bias; Death, Sudden, Cardiac; Defibrillators, Implantable; Ethic	1997
Circadian variation of sustained ventricular tachycardia in patients subject to standard adrenergic blockade. American heart journal, 1997, Volume: 134, Issue:4 Topics: Adrenergic beta-Antagonists; Aged; Amiodarone; Anti-Arrhythmia Agents; Circadian Rhythm; Female; Hum	1997
Use of telemetered permanent pacemaker intracardiac electrograms to diagnose ventricular tachycardia. The American journal of cardiology, 1997, Dec-01, Volume: 80, Issue:11 Topics: Anti-Arrhythmia Agents; Electrocardiography; Heart Rate; Humans; Male; Middle Aged; Pacemaker, Artif	1997
Sotalol associated polymorphic ventricular tachycardia and coronary spasm. Heart (British Cardiac Society), 1998, Volume: 79, Issue:5 Topics: Adrenergic beta-Antagonists; Coronary Vasospasm; Electrocardiography, Ambulatory; Ergonovine; Humans	1998
Is hospital admission for initiation of antiarrhythmic therapy with sotalol for atrial arrhythmias required? Yield of in-hospital monitoring and prediction of risk for significant arrhythmia complications. Journal of the American College of Cardiology, 1998, Volume: 32, Issue:1 Topics: Aged; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrial Flutter; Bradycardia	1998
Use-dependent electrophysiologic effects of DL-sotalol and modulation by isoproterenol in the human ventricle. Japanese heart journal, 1998, Volume: 39, Issue:2 Topics: Action Potentials; Adult; Aged; Anti-Arrhythmia Agents; Cardiotonic Agents; Drug Interactions; Elect	1998
Polymorphic ventricular tachycardias induced by D-sotalol and phenylephrine in canine preparations of atrioventricular block: initiation in the conduction system followed by spatially unstable re-entry. Cardiovascular research, 1998, Volume: 38, Issue:3 Topics: Adrenergic alpha-Agonists; Analysis of Variance; Animals; Anti-Arrhythmia Agents; Dogs; Electrocardi	1998
A comparison of electrophysiologic properties between responders and non-responders to DL-sotalol among patients with ventricular tachyarrhythmia. Importance of the lack of a reverse use-dependent effect on ventricular refractoriness to responders. Japanese heart journal, 1998, Volume: 39, Issue:5 Topics: Action Potentials; Adrenergic beta-Agonists; Adult; Aged; Anti-Arrhythmia Agents; Electrocardiograph	1998
Rate and time dependent effects of D-sotalol on the monophasic action potential after sudden increase of the heart rate. Pacing and clinical electrophysiology : PACE, 1999, Volume: 22, Issue:1 Pt 1 Topics: Action Potentials; Aged; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Electrophysiology; Hear	1999
Predictability of response rates, efficacy, risks, and intolerance with sotalol when used for sustained ventricular arrhythmias. American heart journal, 1999, Volume: 137, Issue:2 Topics: Anti-Arrhythmia Agents; Humans; Sotalol; Tachycardia, Ventricular; Ventricular Fibrillation	1999
Long-term reproducibility of electrophysiologically guided therapy with sotalol in patients with ventricular tachyarrhythmias. Journal of the American College of Cardiology, 1999, Volume: 33, Issue:7 Topics: Anti-Arrhythmia Agents; Electrophysiology; Female; Follow-Up Studies; Humans; Male; Middle Aged; Rec	1999
Prospective clinical evaluation and follow-up of a cohort of consecutive VT/VF patients, using a staged-care protocol, including coronary arteriography, programmed electrical stimulation and cardiac surgery. Giornale italiano di cardiologia, 1999, Volume: 29, Issue:10 Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Cardiac Catheterization; Cardiac	1999
Sustained ventricular tachycardia and its successful prophylaxis during high-dose bolus interleukin-2 therapy for metastatic renal cell carcinoma. American journal of clinical oncology, 2000, Volume: 23, Issue:1 Topics: Anti-Arrhythmia Agents; Antineoplastic Agents; Carcinoma, Renal Cell; Humans; Interleukin-2; Kidney	2000
Life-threatening ventricular arrhythmias associated with giant cell myocarditis (possibly sarcoidosis). The American journal of cardiology, 2000, May-15, Volume: 85, Issue:10 Topics: Anti-Arrhythmia Agents; Anti-Inflammatory Agents; Diagnosis, Differential; Female; Humans; Middle Ag	2000
Heart rate dynamics at the onset of ventricular tachyarrhythmias as retrieved from implantable cardioverter-defibrillators in patients with coronary artery disease. Circulation, 2000, May-23, Volume: 101, Issue:20 Topics: Adrenergic beta-Antagonists; Aged; Anti-Arrhythmia Agents; Coronary Disease; Defibrillators, Implant	2000
Infarct related artery patency: relation to serial electropharmacological studies and outcome in patients with previous myocardial infarction and ventricular tachyarrhythmias. Pacing and clinical electrophysiology : PACE, 2000, Volume: 23, Issue:5 Topics: Aged; Anti-Arrhythmia Agents; Cardiac Pacing, Artificial; Coronary Angiography; Death, Sudden, Cardi	2000
Comparison of the long-term efficacy of implantable defibrillators and sotalol for documented spontaneous sustained ventricular tachyarrhythmias secondary to coronary artery disease. Australian and New Zealand journal of medicine, 1999, Volume: 29, Issue:3 Topics: Aged; Anti-Arrhythmia Agents; Coronary Disease; Defibrillators, Implantable; Female; Humans; Male; M	1999
Clusters of ventricular tachycardias signify impaired survival in patients with idiopathic dilated cardiomyopathy and implantable cardioverter defibrillators. Journal of the American College of Cardiology, 2000, Volume: 36, Issue:2 Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiomyopathy, Dilated; Defibrillators, Implantable; Hear	2000
Demonstration of transient entrainment in monomorphic sustained ventricular tachycardia associated with cardiac sarcoidosis. Japanese circulation journal, 2000, Volume: 64, Issue:8 Topics: Cardiomyopathies; Electric Stimulation Therapy; Electrocardiography; Humans; Male; Middle Aged; Pred	2000
[Action of sotalol on high-amplification electrocardiogram]. Archives des maladies du coeur et des vaisseaux, 2000, Volume: 93, Issue:3 Topics: Adult; Aged; Anti-Arrhythmia Agents; Electrocardiography; Female; Humans; Male; Middle Aged; Sotalol	2000
[Role of determination of QT dispersal intervals in anti-arrhythmia therapy]. Vnitrni lekarstvi, 1999, Volume: 45, Issue:8 Topics: Adrenergic beta-Antagonists; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Electrocar	1999
"Stable" ventricular tachycardia is not a benign rhythm : insights from the antiarrhythmics versus implantable defibrillators (AVID) registry. Circulation, 2001, Jan-16, Volume: 103, Issue:2 Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Controlled Clinical Trials as Topic; Defibrillators, Impla	2001
Phase 2 early afterdepolarization as a trigger of polymorphic ventricular tachycardia in acquired long-QT syndrome : direct evidence from intracellular recordings in the intact left ventricular wall. Circulation, 2001, Jun-12, Volume: 103, Issue:23 Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Dogs; Dose-Response Relationship, Drug; Electroc	2001
Correlation between the effective refractory period and activation-recovery interval calculated from the intracardiac unipolar electrogram of humans with and without dl-sotalol treatment. Japanese circulation journal, 2001, Volume: 65, Issue:8 Topics: Adolescent; Adult; Aged; Anti-Arrhythmia Agents; Child; Electrocardiography; Electrophysiologic Tech	2001
[Effect of sotalol on systemic hemodynamics and electrophysiology in patients with life-threatening ventricular tachyarrhythmias]. Zhonghua nei ke za zhi, 1999, Volume: 38, Issue:1 Topics: Administration, Oral; Adult; Aged; Anti-Arrhythmia Agents; Electrophysiology; Female; Hemodynamics;	1999
Multi-morphology wide QRS tachycardias in a patient without structural heart disease: an unusual presentation of ventricular tachycardia. Japanese heart journal, 2001, Volume: 42, Issue:5 Topics: Anti-Arrhythmia Agents; Catheter Ablation; Defibrillators, Implantable; Electrocardiography; Humans;	2001
Frequency dependent effects of d-sotalol and amiodarone on the action potential duration of the human right ventricle. Pacing and clinical electrophysiology : PACE, 1992, Volume: 15, Issue:11 Pt 2 Topics: Action Potentials; Administration, Oral; Aged; Amiodarone; Cardiac Pacing, Artificial; Female; Heart	1992
Dual chamber rate responsive pacing to allow sotalol therapy for ventricular tachycardia. Pacing and clinical electrophysiology : PACE, 1992, Volume: 15, Issue:11 Pt 2 Topics: Bradycardia; Cardiac Pacing, Artificial; Female; Humans; Male; Middle Aged; Pacemaker, Artificial; S	1992
Effects of sotalol on the signal-averaged electrocardiogram in patients with sustained ventricular tachycardia: relation to suppression of inducibility and changes in tachycardia cycle length. Journal of the American College of Cardiology, 1992, Nov-01, Volume: 20, Issue:5 Topics: Capsules; Cardiac Pacing, Artificial; Electrocardiography; Heart Rate; Humans; Sotalol; Tachycardia,	1992
The advantage of d-sotalol over dl-sotalol in a patient with ventricular arrhythmias and comorbid bronchospasm. Chest, 1992, Volume: 102, Issue:5 Topics: Bronchial Spasm; Humans; Lung Diseases, Obstructive; Male; Middle Aged; Sotalol; Stereoisomerism; Sy	1992
Efficacy of flecainide, sotalol, and verapamil in the treatment of right ventricular tachycardia in patients without overt cardiac abnormality. British heart journal, 1992, Volume: 68, Issue:4 Topics: Adult; Aged; Electric Stimulation; Exercise Test; Flecainide; Humans; Male; Middle Aged; Sotalol; Ta	1992